2019A N N UA L R E P O RT

Continued over page

2019 was a successful and pivotal year for us at the Lions Eye Institute, characterised by:

Significant advances in our scientific endeavours;

Consistently high numbers of patients and surgeries;

Strong dedication to community outreach and teaching.

Every day our dedicated team works towards our core purpose – to prevent and cure blindness and eye disease. We aim to make a difference to people’s lives through sight-saving research and treatments.

However, change is our constant companion, and we are writing this report at a time of major global transformation due to the COVID-19 pandemic. At the Lions Eye Institute, COVID-19 has meant significant shifts in how we see and treat patients, our funding and cost structures, research operations and our working arrangements, among other changes. Despite the pandemic creating high levels of uncertainty, we have had to act decisively to mitigate the various health, social, emotional and financial risks inherent in the spread of the virus.

We are pleased to report that the changes we made early in the crisis – including temperature screening for all staff and visitors, enhancements to our hygiene, cleaning and Personal Protective Equipment (PPE) use, and social distancing measures – have held us in good stead to withstand the threat of infection. In tandem with this response,

we undertook a range of initiatives including financial modelling, cost reduction, workforce planning and rationalisation of work plans and organisational structures. Significantly, we used the crisis period to bring forward some of the projects outlined in our Strategic Plan (2020-2023), such as the digitisation of medical records and introduction of our patient Care Centre.

2019 provided a solid foundation for the turbulence of 2020, and we can look back with pride on the achievements of our 36th year.

Our talented researchers and clinicians don’t work for kudos or glory, nonetheless their achievements in 2019 were well recognised, and included the awarding of the Eureka Prize for Scientific Research to Professor Mariapia Degli-Esposti and her team, Dr Angus Turner being named Western Australian of the Year (Professions) and Professors David Mackey AO and Dao-Yi Yu AM receiving Queen’s Birthday Honours.

In Broome, the new North West Hub started transformation towards becoming a reality that will provide critically needed eye health delivery across the north west of WA.

LEI entered into a commercial collaboration partnership with PYC Therapeutics to develop drugs for Retinitis Pigmentosa, forming the joint venture company Vision Pharma.

We built on our long-standing ties with Indonesia through the launch of the game-changing Virna Glaucoma Drainage Device,

We are pleased to present the Annual Report for the year ended 31 December 2019.

Message from our CHAIRMAN and our MANAGING DIRECTOR

• The annual Visionaries luncheon was held at the UWA Club and featured LEI guest speakers Dr Antony Clark (myopia) and Dr Livia Carvalho (gene therapy approaches for inherited blindness).

• The LEI commenced a partnership with UWA to establish a Doctorate of Optometry program, which will commence in 2021.

• The LEI hosted a substantial number of education and professional meetings, including 10 ophthalmologist colloquiums, 10 retina case conferences, five clinical workshops and three lectures for UWA third year medical students, two RANZCO inter-hospital meetings, three WA Day Hospital meetings and RANZCO exams.

• Dr Hessom Razavi was awarded the Australian Book Review’s Behrouz Boochani Fellowship.

COMMUNITY AND CORPORATE

• Dr Erica Smyth AC was appointed to the LEI Board.

• Professor Bill Morgan was appointed to the role of LEI Managing Director, just the third MD in the Institute’s 36-year history.

• The LEI’s inaugural Research Week was held in October and included a series of well-attended eye health and research lectures. An art-science sensory exhibition featured the work of vision-impaired artist, Dr Erica Tandori, sculptor Robert Hitchcock and LEI researchers Dr Valentina Voigt, Dr Serani van Dommelen, Dr Carla Mellough and Dr Livia Carvalho. ARC Australian Laureate Fellow, Professor Jamie Rossjohn from the Monash Biomedicine Discovery Institute spoke at the event.

CLINICAL

SERVICES

• The LEI’s new Midland clinic opened in January and throughout 2019 saw 700 patients.

• A substantial renovation of the LEI Murdoch clinic commenced.

• The clinic undertook almost 58,000 consultations and more than 4,300 surgeries and minor procedures.

CLINICAL TRIALS

The Clinical Trials Unit

managed 22 sponsored trials, eight investigator initiated studies and more

than 20 external studies.

Almost 1,400 patients and volunteers participated in trials and studies, with more than 2,000 visits to the clinic.

The sponsored trials included phase 2, 3 and 4 studies that are investigating new treatments for conditions such as inflammatory and infectious eye diseases, diabetic macular oedema, macular telangiectasia, wet and dry age related macular degeneration, retinal vein occlusion and genetic eye disease.

Highlights 2019

co-developed by Professor Bill Morgan and Dr Virna Oktariana. Our Indonesian links were strengthened with the signing of MOUs with Indonesian universities.

Collaborations with research peers and universities around the world continue apace, as did our strong and mutually beneficial relationships with organisations such as Vision 2020 Australia, AAMRI and RANZCO.

We commenced a partnership with The University of Western Australia to introduce a Doctorate of Optometry program to WA in 2021, a move that will produce more vitally needed eye health professionals.

The financial result for 2019 is an unusually large surplus of $8.5m, underpinned by $6m in earnings from investments. During the year we realised a $2.3m profit from the sale of the company’s stake in a US biotechnology company which among other activities is commercialising intellectual property developed at the Lions Eye Institute, and gratefully received $2.8m in donations and bequests which helped enormously in funding our health and medical research and the infrastructure that supports it. Our Clinical Trials operation in particular went from strength to strength during the year, and thanks to their contribution along with our core Clinical Services, solid Outback Vision performance, and growing Eye Bank community service we are soundly placed for future sustainability. Thanks to an accumulated $54m of

net assets built up over the 37 years since we were first incorporated, our balance sheet is strong and the Institute is in a sound financial position notwithstanding the impact of COVID-19 in 2020 and the uncertainty it continues to bring for the coming year.

Commencement of work on our 2020-2023 Strategic Plan and Research Plan during 2019 has given us an excellent aspirational roadmap for building on our strong legacy through new and innovative programs, ensuring that our 40th anniversary in 2023 will be a celebration of sustainable success.

We are excited about plans for growth and renewal, including a focus on increasing our research capacity, efficiency and productivity changes in our clinical operations, a revitalised governance structure, and building our community and outreach footprint.

The impact of COVID-19 will be that we embrace a ‘new normal’. We are aware that the virus will continue to dictate changes to our operations for some time to come, and we are well positioned to ride out the highs and lows of the journey.

In closing, the achievements of the Institute would not be possible without the dedication of our outstanding employees, and we thank them for their hard work and commitment.

Thank you also to our Board of Directors, leadership team and the Lions Save-Sight Foundation, ably headed by Chairman Ambrose Depiazzi. A special thanks also to our tremendous supporters.

Message from our CHAIRMAN and our MANAGING DIRECTOR (cont)

Peter Forbes Chairman

Professor Bill Morgan Managing Director

INTERNATIONAL

The Virna Glaucoma Drainage Device, co-invented by the LEI’s Professor Bill Morgan and Indonesian ophthalmologist Dr Virna Oktariana, was launched in Jakarta in June and has helped save the sight of thousands of Indonesians with glaucoma.

In November, the LEI signed Memorandums of Understanding with Universitas Indonesia in Jakarta and Universitas Udayana in Bali. The LEI also has a long-standing MOU with Universitas Airlangga in Surabaya.

Six ophthalmologists from Indonesia and Nigeria undertook observerships with LEI clinicians.

RESEARCH

• Professor Mariapia Degli-Esposti, Head of Experimental Immunology at LEI and Professor (Research) Microbiology and Monash University, was awarded the Eureka Prize for Scientific Research, for work in understanding cytomegalovirus (CMV) and immune system responses. Her team includes the LEI’s Dr Chris Andoniou and Peter Fleming. Professor Degli-Esposti published a landmark article in the highly regarded Science journal.

• Queen’s Birthday Honours were awarded to Professor David Mackey AO and Professor Dao-Yi Yu AM.

• The LEI entered into a commercial collaboration partnership with PYC Therapeutics to develop drugs to treat Retinitis Pigmentosa, harnessing the results of decades of splice therapy and cell penetrating peptides, Australian Inherited Diseases Registry data, and our own expertise in stem cell retinal disease modelling.

• The 1000 to 1000 Challenge was launched by GEnE Warriors, a charity founded by Perth’s Doak family to find a treatment or cure for Usher Syndrome and other vision and hearing disorders. The Lions Eye Institute is affiliated with the Challenge, which involves Australian schools in fundraising.

• Professor Keith Martin, Managing Director of the Centre for Eye Research Australia (CERA), presented the 20th Ian Constable Lecture on ‘Glaucoma: What’s Next on the Horizon?’

• LEI embarked on work with the National Aeronautics and Space Administration (NASA) to uncover the link between changes in intracranial pressure (ICP) and astronauts’ loss of vision.

• Dr Raymond Wong, a stem cell biologist at CERA, presented the annual Miocevich Lecture on ‘Advances for Stem Cell Research in Retinal Diseases’.

LIONS OUTBACK VISION

Dr Angus Turner, McCusker Director Lions Outback Vision, was named 2019 Western Australian of the Year (Professions) and was a finalist in the Australian of the Year Awards.

The North West Eye Health Hub in Broome became a reality with the donation by the WEN Giving Foundation and Hawaiian of the former backpacker hostel, the Kimberley Klub.

Outreach patients increased

from 8,868 in 2018 to 9,670 in 2019

(including optometry and telehealth).

The Federal Government committed funding towards refurbishing the Kimberley Klub to become an inter-disciplinary eye health clinic.

Development of the LEI’s Reconciliation Action Plan commenced.

Highlights 2019

We acknowledge the traditional owners and people of the lands on which we operate, and honour their elders past, present and future.

Continued overleaf

CONTACT DETAILS

2 Verdun Street

Nedlands WA 6009

(08) 9381 0777

www.lei.org.au

Snapshot 2019

1,346

253 CORNEAL TRANSPLANTSincluding 29 corneas exported interstate or to New Zealand to assist with demand.

This was the highest number of transplants since the inception of the Lions Eye Bank in 1986.

125 sclerae collectedby the Lions Eye Bank, and 59 posterior chambers (tissue) provided to LEI research groups

seen by the Lions Outback Vision Van, and 1,013 patients seen by LOV in Perth

25,006 kilometres drivenby the Vision Van, including 422 driving hours

57,575 NUMBER OF CONSULTATIONS

4,385 surgeries & minor proceduresundertaken. LOV completed 725 surgeries and minor procedures

79% FEMALESin LEI workforce

of 230, 21% MALESF M

4,183 DONATIONS to the Lions Eye

Institute, totalling

$1.73 MILLION

$6.509m in research grants, including Australian competitive grants, government grants, international and other grants

$961,748 received from

bequestshighly experienced

clinicians

16

3,044 outreach patients

COMPREHENSIVE EYE EXAMINATIONS conducted by Lions Optics optometrists

1,955 PAIRS of spectacles dispensed to outreach patients, 91% of whom were Indigenous

51%of outreach patients seen were Indigenous

with services received in the clinic

93.8% patients happy or very happy

NINETYresearch papers published

33 volunteers in the Clinic Concierge program

telehealth consultations

5 PATENTS

7744552019 ANNUAL REPORT

2019 was a successful and pivotal year for us at the Lions Eye Institute, characterised by:

Significant advances in our scientific endeavours;

Consistently high numbers of patients and surgeries;

Strong dedication to community outreach and teaching.

Every day our dedicated team works towards our core purpose – to prevent and cure blindness and eye disease. We aim to make a difference to people’s lives through sight-saving research and treatments.

However, change is our constant companion, and we are writing this report at a time of major global transformation due to the COVID-19 pandemic. At the Lions Eye Institute, COVID-19 has meant significant shifts in how we see and treat patients, our funding and cost structures, research operations and our working arrangements, among other changes. Despite the pandemic creating high levels of uncertainty, we have had to act decisively to mitigate the various health, social, emotional and financial risks inherent in the spread of the virus.

We are pleased to report that the changes we made early in the crisis – including temperature screening for all staff and visitors, enhancements to our hygiene, cleaning and Personal Protective Equipment (PPE) use, and social distancing measures – have held us in good stead to withstand the threat of infection. In tandem with this response,

we undertook a range of initiatives including financial modelling, cost reduction, workforce planning and rationalisation of work plans and organisational structures. Significantly, we used the crisis period to bring forward some of the projects outlined in our Strategic Plan (2020-2023), such as the digitisation of medical records and introduction of our patient Care Centre.

2019 provided a solid foundation for the turbulence of 2020, and we can look back with pride on the achievements of our 36th year.

Our talented researchers and clinicians don’t work for kudos or glory, nonetheless their achievements in 2019 were well recognised, and included the awarding of the Eureka Prize for Scientific Research to Professor Mariapia Degli-Esposti and her team, Dr Angus Turner being named Western Australian of the Year (Professions) and Professors David Mackey AO and Dao-Yi Yu AM receiving Queen’s Birthday Honours.

In Broome, the new North West Hub started transformation towards becoming a reality that will provide critically needed eye health delivery across the north west of WA.

LEI entered into a commercial collaboration partnership with PYC Therapeutics to develop drugs for Retinitis Pigmentosa, forming the joint venture company Vision Pharma.

We built on our long-standing ties with Indonesia through the launch of the game-changing Virna Glaucoma Drainage Device,

We are pleased to present the Annual Report for the year ended 31 December 2019.

Message from our CHAIRMAN and our MANAGING DIRECTOR

MIS

SION and VALUES

Integrity : we do what we say we’re going to do, and are accountable, transparent and responsible in our actions.

Care : we consider and respect our patients, collaborators and each other.

Curiosity : we ask questions, are interested and never stop learning.

Impact : we make a positive difference to the lives of others and the communities in which we operate.

Unity : we support each other and work as one to achieve common goals.

Values

Purpose

To prevent and cure blindness

and eye disease.Vision

Better vision for all.

We acknowledge the traditional owners and people of the lands on which we operate, and honour their elders past, present and future.

CONTACT DETAILS

2 Verdun Street

Nedlands WA 6009

(08) 9381 0777

www.lei.org.au

Snapshot 2019

1,346

253 CORNEAL TRANSPLANTSincluding 29 corneas exported interstate or to New Zealand to assist with demand.

This was the highest number of transplants since the inception of the Lions Eye Bank in 1986.

125 sclerae collectedby the Lions Eye Bank, and 59 posterior chambers (tissue) provided to LEI research groups

seen by the Lions Outback Vision Van, and 1,013 patients seen by LOV in Perth

25,006 kilometres drivenby the Vision Van, including 422 driving hours

57,575NUMBER OF CONSULTATIONS

4,385 surgeries & minor proceduresundertaken. LOV completed 725 surgeries and minor procedures

79% FEMALESin LEI workforce

of 230, 21% MALES F M

4,183 DONATIONS to the Lions Eye

Institute, totalling

$1.73 MILLION

$6.509m in research grants, including Australian competitive grants, government grants, international and other grants

$961,748 received from

bequestshighly experienced

clinicians

16

3,044 outreach patients

COMPREHENSIVE EYE EXAMINATIONS conducted by Lions Optics optometrists

1,955 PAIRS of spectacles dispensed to outreach patients, 91% of whom were Indigenous

51%of outreach patients seen were Indigenous

with services received in the clinic

93.8% patients happy or very happy

NINETYresearch papers published

33 volunteers in the Clinic Concierge program

telehealth consultations

5 PATENTS

774455

GOVERNANCE and LEADERSHIP

The Lions Eye Institute is committed to strong and effective governance and leadership, and is proud of its high-calibre Board and Executive group.

OUR BOARD

The Board comprises leaders from the business, not-for-profit, health and university sectors, who undertake governance, strategy and risk oversight of the Lions Eye Institute. In meeting its obligations to the community, the Institute adheres to high standards of corporate governance as a company limited by guarantee with not-for-profit and Deductible Gift Recipient status.

Non-Executive Director Dr Margaret Crowley BA, M.EdSt, PhD, GAICD joined the Board in 2016. She is an experienced CEO and Board Director and a Graduate of the Australian Institute of Company Directors. She has held senior executive positions in State and National Governments, and in Universities and the not-for-profit sector, most recently as CEO of the Association for the Blind of WA Inc. for 15 years.

Non-Executive Director Tony Joyner joined the Board in 2013. He has over 25 years’ experience as a commercial and corporate lawyer and is the Managing Partner of the Perth office of Herbert Smith Freehills. Mr Joyner has particular expertise in corporate and commercial law as it relates to technology and intellectual property matters. He is the Chair of Scitech, and a General Council Member and Committee Chair of the Chamber of Commerce and Industry of WA.

Non-Executive Director Professor Grant Waterer MBBS, Ph.D., MBA, FRACP, FCCP joined the Board in 2018. A respiratory specialist, he is the Director of Clinical Services at Royal Perth Hospital and Professor of Medicine at The University of Western Australia, as well as being

an adjunct Professor of Medicine at Northwestern University, Chicago and adjunct Professor of Medicine at Curtin University.

Non-Executive Director Dr Erica Smyth AC, FTSE, FAIC joined the Board in 2019. She has 45 years’ experience in the mineral and petroleum industries, initially as a minerals exploration geologist and later in project management, government approvals, corporate affairs and community interactions. Dr Smyth is the Chair of the Ministerial Advisory Boards for the National Offshore Petroleum Safety and Environment Management Authority (NOPSEMA) and the Defence First Principles Oversight Board as well as the Industry Advisory Board for the ARC Centre for Mine Site Restoration.

Professor Ian McAllister MBBS, DM (PhD), FRANZCO, FRACS joined the Board in 2010. He is a consultant ophthalmologist at the Lions Eye Institute and Professor of Ophthalmology at The University of Western Australia. He is actively involved in research for cures for vitreoretinal disorders, especially retinal vascular disorders, and has held 10 NHMRC grants in this area as well as numerous minor grants.

Clinic

In our clinical operations, we are committed to having clear responsibilities for managing safety and quality of care, as well as adherence to National Safety and Quality Health Services Standards and the Licensing Standards for the Arrangements for Management, Staffing and Equipment in Day Hospitals Class A.

The Medical Advisory Committee, comprising Dr Steve Wiffen (Chair), Dr Chandra Balaratnasingam, Dr Mei-Ling Tay-Kearney, Dr Antonio Giubilato, Professor Ian McAllister and Professor Bill Morgan, contributes to the governance and oversight of the operations of clinical services, and effective delivery of the clinical services strategy.

The Clinicians Forum is a representative committee comprising all LEI clinicians, that considers and advises on matters relating to patient safety, quality of care, infection control and other risks, and refers issues for action to the MAC. The Chair is Dr Steve Wiffen.

The LEI’s Quality and Safety Committee consists of representatives from areas of the LEI that relate to all quality and safety matters, including clinical services. The Committee oversees relevant policies, and promotes and monitors improvements in the quality and safety of LEI services.

The Credentialing Committee initiates and reviews the credentialing of high quality clinicians appointed to the LEI, and undertakes regular reviews. The Chair is Dr Steve Wiffen.

OUR GOVERNANCE FRAMEWORK

Our governance framework is designed to ensure we operate strategically, with strong leadership and best practice decision-making.

Non-Executive Chairman Peter Forbes FCA, FAICD joined the Board in 2014. A chartered accountant, he is the former CEO of specialist medical indemnity provider, MDA National and Managing Director of its wholly owned insurer, MDA National Insurance. He is a Non-Executive Director on the East Metropolitan Health Service Board, Chair of the Local Government Insurance Scheme WA and an Independent Committee Member of the WA Law Society’s professional indemnity committee.

Managing Director Professor Bill Morgan MB BS, PhD, FRANZCO was appointed Managing Director of the Lions Eye Institute in 2019. He has been a leading ophthalmologist and medical researcher at the LEI for 27 years and is also Professor of Ophthalmology at The University of Western Australia and consultant ophthalmologist at Royal Perth Hospital and Perth Children’s Hospital.

Non-Executive Director Richard Alder joined the Board in 2017. He has worked in the securities industry since 1965 and worked with JB Were for 31 years – in Melbourne, London, and as a Partner and Director of the Perth office for 17 years until 2003.

Non-Executive Director Rudolf Brunovs joined the Board in 2005. He retired as a partner of the chartered accounting firm Ernst & Young after 27 years as a partner in a number of their offices. He is currently a Director and the Principal of Mainstay Consulting Pty Ltd and a Director of Deep Yellow Limited. Mr Brunovs is a Fellow of the Institute of Chartered Accountants and the Australian Institute of Company Directors, and holds a Masters of Business Administration.

Research

Our research governance structure comprises four principal committees:

Research and University Relationships Committee (RAUR)

This committee has the broadest oversight of research capacity, governance and strategy. It provides confidence to the LEI Board that all research undertaken under the LEI banner is documented and compliant with LEI research governance and standards. The RAUR is chaired by Board member, Professor Grant Waterer, and includes Board members and LEI executive.

Scientific Advisory Panel (SAP)

This committee drives the research strategy and the processes to support implementation of the strategy. It engages with a range of external experts to develop and renew strategic directions and inform LEI’s research strategy, as well as providing oversight and guidance to increase research governance capability and research outputs. The SAP is chaired by the Managing Director, Professor Bill Morgan, and includes members of the LEI Board as well as senior internal and external scientists.

Research Implementation Group (RIG)

The RIG aims to build research capability and allocate small internal grants to LEI researchers. It helps to enhance our strong research culture and build alliances for clinical trials. The RIG is chaired by senior LEI scientist, Dr Sam McLenachan, and includes senior research management and scientists.

Clinical Trials and Research Committee (CT&RC)

This committee builds research capability, culture and alliances for clinical trials. It supports the research governance framework, ensuring research is high quality, of scientific merit and ethical. It also ensures clinical trials are undertaken fairly and sustainably in line with LEI strategic objectives, and facilitates the growth of translational research. The Committee is chaired by LEI clinician scientist, Dr Antony Clark, and includes the Manager Clinical Trials and key executives.

1

2

3

4

Board Committees

The sub-committees of the LEI Board provide oversight of key areas and include:

– Finance, Audit and Risk Committee

– Development and Advocacy Committee

– Investment Committee

Other Leadership Forum members include:

• Lisa Buckland, Manager Lions Eye Bank

• Tammy Corica, Manager Clinical Trials

• Amanda Poulson, Manager Clinic*

• Christine Stott, Manager Lions Outback Vision

• Mary Vukmirovic, Manager Research Support

OUR EXECUTIVE

Our Executive group oversees the strategic and operational activities of the Lions Eye Institute.

Professor Bill Morgan

Managing Director and Director of Research

Chris Whitelock

Chief Operating Officer and Chief Financial Officer

Tania Hudson

Chief of Staff

Jordana Norwell

Director People and Culture

Michelle Hutchins

Director Communications and Philanthropy

Associate Professor Angus Turner

McCusker Director Lions Outback Vision

Clinical Associate Professor Hessom Razavi

Director Community and Education

Dr Steve Wiffen

Director Lions Eye Bank and Clinical Lead

As per Board listing. Mr Whitelock is a chartered accountant with over 30 years’ experience and was first appointed Chief Financial Officer and Company Secretary of the Institute in January 2014. He was later appointed Chief Operating Officer in October 2017. After qualifying with and specialising in small business for one of the big four accounting and auditing firms, Mr Whitelock worked in listed companies and entrepreneurial start-ups. For the past 17 years he has worked in the not-for-profit sector. He is responsible for managing finances, governance, risk and other corporate services at the Institute.

Ms Hudson was appointed Chief of Staff in December 2019, and was formerly Director Development and Communications at the Institute. Ms Hudson is a communications professional who has had a diverse career in all areas of stakeholder relations, including senior roles with the Minderoo Group, Rio Tinto and ANZ. Also a former business journalist at The Age and Courier-Mail newspapers, Ms Hudson has qualifications from the University of Queensland and University of Cambridge, and is a Graduate of the Australian Institute of Company Directors. She sits on a not-for-profit creative sector Board.

Ms Norwell, who joined the Institute in June 2019, is a human resources professional with 15 years of diverse experience across a range of industries within the private sector. Her experience includes roles with large internationally based organisations as well as Australian mid-sized organisations and not-for-profits. Ms Norwell graduated from The University of Western Australia with a Master of Commerce specialising in Human Resource Management & Industrial Relations and a Bachelor of Arts degree majoring in Psychology. Ms Norwell is also a certified professional member of the Australian Human Resources Institute.

Ms Hutchins, who joined the Institute in October 2019, is a senior marketing and engagement manager with over 20 years’ experience. Since qualifying with a BA of Commerce and a BA Social Science from Curtin University of Technology, Ms Hutchins has worked across a number of industries, including real estate and property, construction, insurance, start-ups and not-for-profit. She is responsible for the fundraising, marketing communications, digital marketing and social media strategies at the Institute.

Dr Turner is actively involved in the delivery of specialist outreach services to remote and Indigenous communities in the Kimberley, Pilbara, Goldfields, Midwest and Great Southern regions. An Associate Professor at UWA, Dr Turner is engaged in a number of research projects at the LEI, focusing on service delivery for remote and Indigenous people. He is also a clinical lecturer for the Rural Clinical School at UWA, Curtin University and Notre Dame. Dr Turner completed medical training at UWA before studying at Oxford University and completing a Masters of Evidence Based Medicine. Ophthalmology training was undertaken in Melbourne.

Dr Razavi completed his ophthalmology training in Western Australia, before undertaking two fellowships. He was the inaugural Lions Outback Fellow, providing outreach services to remote and Indigenous communities in WA. This was followed by a medical retina fellowship at the Royal Victorian Eye and Ear Hospital, and the Centre for Eye Research Australia. Prior to this, Dr Razavi completed a Masters of Public Health in Eye Care at the London School of Hygiene and Tropical Medicine. He is the unit coordinator for ophthalmology teaching at UWA.

Dr Wiffen, a graduate of the University of Queensland Medical School, trained in ophthalmology in WA before undertaking two-year fellowships in cornea and refractive surgery at the Corneo-Plastic Unit, East Grinstead, UK, and the Mayo Clinic, Rochester, Minnesota, USA. He Chairs the LEI Medical Advisory Committee and Clinicians Forum, and has been Director Lions Eye Bank since 1997. Dr Wiffen, who has specialist expertise in corneal transplantation, pterygium and cataract and refractive surgery, is also a Consultant Ophthalmologist at Fremantle Hospital.

OUR PATRON

Professor Constable trained in ophthalmology in New South Wales before being appointed as Clinical Retinal Fellow at the Massachusetts Eye and Ear Infirmary. He later became a consultant surgeon and Lecturer at Harvard University. He was appointed the Foundation Professor of Ophthalmology and retinal surgeon at Royal Perth Hospital in 1975 before establishing the Lions Eye Institute in 1983.

Professor Constable continues to practice as a consultant ophthalmologist at the LEI and at Sir Charles Gairdner Hospital with a special interest in diabetic retinopathy, macular degeneration and second opinions for complex eye problems.

He was Managing Director at the LEI from 1983 to February 2009 and was appointed Patron of the LEI in 2018.

The Patron of the Lions Eye Institute is Professor Ian Constable AO.

OUR LEADERSHIP

Our Leadership Forum provides operational management of the Lions Eye Institute.

* During 2020 the LEI has implemented a number of organisational structure changes, including the appointment of David Harrison to the position of General Manager Clinical Services.

Other Leadership Forum members include:

• Lisa Buckland, Manager Lions Eye Bank

• Tammy Corica, Manager Clinical Trials

• Amanda Poulson, Manager Clinic*

• Christine Stott, Manager Lions Outback Vision

• Mary Vukmirovic, Manager Research Support

OUR EXECUTIVE

Our Executive group oversees the strategic and operational activities of the Lions Eye Institute.

Professor Bill Morgan

Managing Director and Director of Research

Chris Whitelock

Chief Operating Officer and Chief Financial Officer

Tania Hudson

Chief of Staff

Jordana Norwell

Director People and Culture

Michelle Hutchins

Director Communications and Philanthropy

Associate Professor Angus Turner

McCusker Director Lions Outback Vision

Clinical Associate Professor Hessom Razavi

Director Community and Education

Dr Steve Wiffen

Director Lions Eye Bank and Clinical Lead

As per Board listing. Mr Whitelock is a chartered accountant with over 30 years’ experience and was first appointed Chief Financial Officer and Company Secretary of the Institute in January 2014. He was later appointed Chief Operating Officer in October 2017. After qualifying with and specialising in small business for one of the big four accounting and auditing firms, Mr Whitelock worked in listed companies and entrepreneurial start-ups. For the past 17 years he has worked in the not-for-profit sector. He is responsible for managing finances, governance, risk and other corporate services at the Institute.

Ms Hudson was appointed Chief of Staff in December 2019, and was formerly Director Development and Communications at the Institute. Ms Hudson is a communications professional who has had a diverse career in all areas of stakeholder relations, including senior roles with the Minderoo Group, Rio Tinto and ANZ. Also a former business journalist at The Age and Courier-Mail newspapers, Ms Hudson has qualifications from the University of Queensland and University of Cambridge, and is a Graduate of the Australian Institute of Company Directors. She sits on a not-for-profit creative sector Board.

Ms Norwell, who joined the Institute in June 2019, is a human resources professional with 15 years of diverse experience across a range of industries within the private sector. Her experience includes roles with large internationally based organisations as well as Australian mid-sized organisations and not-for-profits. Ms Norwell graduated from The University of Western Australia with a Master of Commerce specialising in Human Resource Management & Industrial Relations and a Bachelor of Arts degree majoring in Psychology. Ms Norwell is also a certified professional member of the Australian Human Resources Institute.

Ms Hutchins, who joined the Institute in October 2019, is a senior marketing and engagement manager with over 20 years’ experience. Since qualifying with a BA of Commerce and a BA Social Science from Curtin University of Technology, Ms Hutchins has worked across a number of industries, including real estate and property, construction, insurance, start-ups and not-for-profit. She is responsible for the fundraising, marketing communications, digital marketing and social media strategies at the Institute.

Dr Turner is actively involved in the delivery of specialist outreach services to remote and Indigenous communities in the Kimberley, Pilbara, Goldfields, Midwest and Great Southern regions. An Associate Professor at UWA, Dr Turner is engaged in a number of research projects at the LEI, focusing on service delivery for remote and Indigenous people. He is also a clinical lecturer for the Rural Clinical School at UWA, Curtin University and Notre Dame. Dr Turner completed medical training at UWA before studying at Oxford University and completing a Masters of Evidence Based Medicine. Ophthalmology training was undertaken in Melbourne.

Dr Razavi completed his ophthalmology training in Western Australia, before undertaking two fellowships. He was the inaugural Lions Outback Fellow, providing outreach services to remote and Indigenous communities in WA. This was followed by a medical retina fellowship at the Royal Victorian Eye and Ear Hospital, and the Centre for Eye Research Australia. Prior to this, Dr Razavi completed a Masters of Public Health in Eye Care at the London School of Hygiene and Tropical Medicine. He is the unit coordinator for ophthalmology teaching at UWA.

Dr Wiffen, a graduate of the University of Queensland Medical School, trained in ophthalmology in WA before undertaking two-year fellowships in cornea and refractive surgery at the Corneo-Plastic Unit, East Grinstead, UK, and the Mayo Clinic, Rochester, Minnesota, USA. He Chairs the LEI Medical Advisory Committee and Clinicians Forum, and has been Director Lions Eye Bank since 1997. Dr Wiffen, who has specialist expertise in corneal transplantation, pterygium and cataract and refractive surgery, is also a Consultant Ophthalmologist at Fremantle Hospital.

OUR PATRON

Professor Constable trained in ophthalmology in New South Wales before being appointed as Clinical Retinal Fellow at the Massachusetts Eye and Ear Infirmary. He later became a consultant surgeon and Lecturer at Harvard University. He was appointed the Foundation Professor of Ophthalmology and retinal surgeon at Royal Perth Hospital in 1975 before establishing the Lions Eye Institute in 1983.

Professor Constable continues to practice as a consultant ophthalmologist at the LEI and at Sir Charles Gairdner Hospital with a special interest in diabetic retinopathy, macular degeneration and second opinions for complex eye problems.

He was Managing Director at the LEI from 1983 to February 2009 and was appointed Patron of the LEI in 2018.

The Patron of the Lions Eye Institute is Professor Ian Constable AO.

OUR LEADERSHIP

Our Leadership Forum provides operational management of the Lions Eye Institute.

* During 2020 the LEI has implemented a number of organisational structure changes, including the appointment of David Harrison to the position of General Manager Clinical Services.

GOVERNANCE and LEADERSHIP

The Lions Eye Institute is committed to strong and effective governance and leadership, and is proud of its high-calibre Board and Executive group.

OUR BOARD

The Board comprises leaders from the business, not-for-profit, health and university sectors, who undertake governance, strategy and risk oversight of the Lions Eye Institute. In meeting its obligations to the community, the Institute adheres to high standards of corporate governance as a company limited by guarantee with not-for-profit and Deductible Gift Recipient status.

Non-Executive Director Dr Margaret Crowley BA, M.EdSt, PhD, GAICD joined the Board in 2016. She is an experienced CEO and Board Director and a Graduate of the Australian Institute of Company Directors. She has held senior executive positions in State and National Governments, and in Universities and the not-for-profit sector, most recently as CEO of the Association for the Blind of WA Inc. for 15 years.

Non-Executive Director Tony Joyner joined the Board in 2013. He has over 25 years’ experience as a commercial and corporate lawyer and is the Managing Partner of the Perth office of Herbert Smith Freehills. Mr Joyner has particular expertise in corporate and commercial law as it relates to technology and intellectual property matters. He is the Chair of Scitech, and a General Council Member and Committee Chair of the Chamber of Commerce and Industry of WA.

Non-Executive Director Professor Grant Waterer MBBS, Ph.D., MBA, FRACP, FCCP joined the Board in 2018. A respiratory specialist, he is the Director of Clinical Services at Royal Perth Hospital and Professor of Medicine at The University of Western Australia, as well as being

an adjunct Professor of Medicine at Northwestern University, Chicago and adjunct Professor of Medicine at Curtin University.

Non-Executive Director Dr Erica Smyth AC, FTSE, FAIC joined the Board in 2019. She has 45 years’ experience in the mineral and petroleum industries, initially as a minerals exploration geologist and later in project management, government approvals, corporate affairs and community interactions. Dr Smyth is the Chair of the Ministerial Advisory Boards for the National Offshore Petroleum Safety and Environment Management Authority (NOPSEMA) and the Defence First Principles Oversight Board as well as the Industry Advisory Board for the ARC Centre for Mine Site Restoration.

Professor Ian McAllister MBBS, DM (PhD), FRANZCO, FRACS joined the Board in 2010. He is a consultant ophthalmologist at the Lions Eye Institute and Professor of Ophthalmology at The University of Western Australia. He is actively involved in research for cures for vitreoretinal disorders, especially retinal vascular disorders, and has held 10 NHMRC grants in this area as well as numerous minor grants.

Clinic

In our clinical operations, we are committed to having clear responsibilities for managing safety and quality of care, as well as adherence to National Safety and Quality Health Services Standards and the Licensing Standards for the Arrangements for Management, Staffing and Equipment in Day Hospitals Class A.

The Medical Advisory Committee, comprising Dr Steve Wiffen (Chair), Dr Chandra Balaratnasingam, Dr Mei-Ling Tay-Kearney, Dr Antonio Giubilato, Professor Ian McAllister and Professor Bill Morgan, contributes to the governance and oversight of the operations of clinical services, and effective delivery of the clinical services strategy.

The Clinicians Forum is a representative committee comprising all LEI clinicians, that considers and advises on matters relating to patient safety, quality of care, infection control and other risks, and refers issues for action to the MAC. The Chair is Dr Steve Wiffen.

The LEI’s Quality and Safety Committee consists of representatives from areas of the LEI that relate to all quality and safety matters, including clinical services. The Committee oversees relevant policies, and promotes and monitors improvements in the quality and safety of LEI services.

The Credentialing Committee initiates and reviews the credentialing of high quality clinicians appointed to the LEI, and undertakes regular reviews. The Chair is Dr Steve Wiffen.

OUR GOVERNANCE FRAMEWORK

Our governance framework is designed to ensure we operate strategically, with strong leadership and best practice decision-making.

Non-Executive Chairman Peter Forbes FCA, FAICD joined the Board in 2014. A chartered accountant, he is the former CEO of specialist medical indemnity provider, MDA National and Managing Director of its wholly owned insurer, MDA National Insurance. He is a Non-Executive Director on the East Metropolitan Health Service Board, Chair of the Local Government Insurance Scheme WA and an Independent Committee Member of the WA Law Society’s professional indemnity committee.

Managing Director Professor Bill Morgan MB BS, PhD, FRANZCO was appointed Managing Director of the Lions Eye Institute in 2019. He has been a leading ophthalmologist and medical researcher at the LEI for 27 years and is also Professor of Ophthalmology at The University of Western Australia and consultant ophthalmologist at Royal Perth Hospital and Perth Children’s Hospital.

Non-Executive Director Richard Alder joined the Board in 2017. He has worked in the securities industry since 1965 and worked with JB Were for 31 years – in Melbourne, London, and as a Partner and Director of the Perth office for 17 years until 2003.

Non-Executive Director Rudolf Brunovs joined the Board in 2005. He retired as a partner of the chartered accounting firm Ernst & Young after 27 years as a partner in a number of their offices. He is currently a Director and the Principal of Mainstay Consulting Pty Ltd and a Director of Deep Yellow Limited. Mr Brunovs is a Fellow of the Institute of Chartered Accountants and the Australian Institute of Company Directors, and holds a Masters of Business Administration.

Research

Our research governance structure comprises four principal committees:

Research and University Relationships Committee (RAUR)

This committee has the broadest oversight of research capacity, governance and strategy. It provides confidence to the LEI Board that all research undertaken under the LEI banner is documented and compliant with LEI research governance and standards. The RAUR is chaired by Board member, Professor Grant Waterer, and includes Board members and LEI executive.

Scientific Advisory Panel (SAP)

This committee drives the research strategy and the processes to support implementation of the strategy. It engages with a range of external experts to develop and renew strategic directions and inform LEI’s research strategy, as well as providing oversight and guidance to increase research governance capability and research outputs. The SAP is chaired by the Managing Director, Professor Bill Morgan, and includes members of the LEI Board as well as senior internal and external scientists.

Research Implementation Group (RIG)

The RIG aims to build research capability and allocate small internal grants to LEI researchers. It helps to enhance our strong research culture and build alliances for clinical trials. The RIG is chaired by senior LEI scientist, Dr Sam McLenachan, and includes senior research management and scientists.

Clinical Trials and Research Committee (CT&RC)

This committee builds research capability, culture and alliances for clinical trials. It supports the research governance framework, ensuring research is high quality, of scientific merit and ethical. It also ensures clinical trials are undertaken fairly and sustainably in line with LEI strategic objectives, and facilitates the growth of translational research. The Committee is chaired by LEI clinician scientist, Dr Antony Clark, and includes the Manager Clinical Trials and key executives.

1

2

3

4

Board Committees

The sub-committees of the LEI Board provide oversight of key areas and include:

– Finance, Audit and Risk Committee

– Development and Advocacy Committee

– Investment Committee

165

PUBLICATIONS 2019

Genetics and Epidemiology

Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol.

McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, Mackey DA, Butler JS, Loughman J.HRB Open Res. 2019 Jul 23;2:15. doi: 10.12688/hrbopenres.12914.1. eCollection 2019.PMID: 32002514

Association of Genetic Variation with Keratoconus.

McComish BJ, Sahebjada S, Bykhovskaya Y, Willoughby CE, Richardson AJ, Tenen A, Charlesworth JC, MacGregor S, Mitchell P, Lucas SEM, Mills RA, Mackey DA, Li X, Wang JJ, Jensen RA, Rotter JI, Taylor KD, Hewitt AW, Rabinowitz YS, Baird PN, Craig JE, Burdon KP.JAMA Ophthalmol. 2019 Dec 19. doi: 10.1001/jamaophthalmol.2019.5293. [Epub ahead of print]PMID: 31855235IF 6.167

Estimation of heritability and familial correlation in myopia is not affected by past sun exposure.

Charng J, Sanfilippo PG, Lingham G, Stevenson LJ, Mackey DA, Yazar S.Ophthalmic Genet. 2019 Dec;40(6): 500-506. doi: 10.1080/13816810.2019. 1696376. Epub 2019 Dec 6.PMID: 31810409IF 1.285

Genome-wide association analysis of 95 549 individuals identifies novel loci and genes influencing optic disc morphology.

Han X, Qassim A, An J, Marshall H, Zhou T, Ong JS, Hassall MM, Hysi PG, Foster PJ, Khaw PT, Mackey DA, Gharahkhani P, Khawaja AP, Hewitt AW, Craig JE, MacGregor S.Hum Mol Genet. 2019 Nov 1;28(21): 3680-3690. doi: 10.1093/hmg/ddz193.PMID: 31809533IF 4.544

Multi-trait genome-wide association study identifies new loci associated with optic disc parameters.

Bonnemaijer PWM, Leeuwen EMV, Iglesias AI, Gharahkhani P, Vitart V, Khawaja AP, Simcoe M, Höhn R, Cree AJ, Igo RP; International Glaucoma

Genetics Consortium; NEIGHBORHOOD consortium; UK Biobank Eye and Vision Consortium, Gerhold-Ay A, Nickels S, Wilson JF, Hayward C, Boutin TS, Polašek O, Aung T, Khor CC, Amin N, Lotery AJ, Wiggs JL, Cheng CY, Hysi PG, Hammond CJ, Thiadens AAHJ, MacGregor S, Klaver CCW, Duijn CMV.Commun Biol. 2019 Nov 27;2:435. doi: 10.1038/s42003-019-0634-9. eCollection 2019.PMID: 31798171 IF under calculation

How does spending time outdoors protect against myopia? A review.

Lingham G, Mackey DA, Lucas R, Yazar S.Br J Ophthalmol. 2019 Nov 13. pii: bjophthalmol-2019-314675. doi: 10.1136/bjophthalmol-2019-314675. [Epub ahead of print] Review.PMID: 31722876IF 3.615

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol.

Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, Doherty P, Adams C, Gardner E, Hogg R, McFarland M, Preston J, Verghis R, Loughman JJ, Flitcroft I, Mackey DA, Lee SS, Hammond C, Congdon N, Clarke M.Br J Ophthalmol. 2019 Oct 25. pii: bjophthalmol-2019-314819. doi: 10.1136/bjophthalmol-2019-314819. [Epub ahead of print]PMID: 31653669IF 3.615

Epha2 genotype influences ultraviolet radiation induced cataract in mice.

Dave A, Craig JE, Skrzypiec K, Quinn S, Barnes M, Di Girolamo N, Mackey DA, Burdon KP, de Iongh RU, Sharma S.Exp Eye Res. 2019 Nov;188:107806. doi: 10.1016/j.exer.2019.107806. Epub 2019 Sep 17.PMID: 31539542IF 2.998

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.

BIRTH-GENE (BIG) Study Working Group, Huang T, Wang T, Zheng Y, Ellervik C, Li X, Gao M, Fang Z, Chai JF, Ahluwalia TVS, Wang Y, Voortman T, Noordam

R, Frazier-Wood A, Scholz M, Sonestedt E, Akiyama M, Dorajoo R, Zhou A, Kilpeläinen TO, Kleber ME, Crozier SR, Godfrey KM, Lemaitre R, Felix JF, Shi Y, Gupta P, Khor CC, Lehtimäki T, Wang CA, Tiesler CMT, Thiering E, Standl M, Rzehak P, Marouli E, He M, Lecoeur C, Corella D, Lai CQ, Moreno LA, Pitkänen N, Boreham CA, Zhang T, Saw SM, Ridker PM, Graff M, van Rooij FJA, Uitterlinden AG, Hofman A, van Heemst D, Rosendaal FR, de Mutsert R, Burkhardt R, Schulz CA, Ericson U, Kamatani Y, Yuan JM, Power C, Hansen T, Sørensen TIA, Tjønneland A, Overvad K, Delgado G, Cooper C, Djousse L, Rivadeneira F, Jameson K, Zhao W, Liu J, Lee NR, Raitakari O, Kähönen M, Viikari J, Grote V, Langhendries JP, Koletzko B, Escribano J, Verduci E, Dedoussis G, Yu C, Tham YC, Lim B, Lim SH, Froguel P, Balkau B, Fink NR, Vinding RK, Sevelsted A, Bisgaard H, Coltell O, Dallongeville J, Gottrand F, Pahkala K, Niinikoski H, Hyppönen E, Pedersen O, März W, Inskip H, Jaddoe VWV, Dennison E, Wong TY, Sabanayagam C, Tai ES, Mohlke KL, Mackey DA, Gruszfeld D, Deloukas P, Tucker KL, Fumeron F, Bønnelykke K, Rossing P, Estruch R, Ordovas JM, Arnett DK, Meirhaeghe A, Amouyel P, Cheng CY, Sim X, Teo YY, van Dam RM, Koh WP, Orho-Melander M, Loeffler M, Kubo M, Thiery J, Mook-Kanamori DO, Mozaffarian D, Psaty BM, Franco OH, Wu T, North KE, Davey Smith G, Chavarro JE, Chasman DI, Qi L.JAMA Netw Open. 2019 Sep 4;2(9):e1910915. doi: 10.1001/jamanetworkopen.2019.10915.PMID: 31539074

The challenge of an adequate outcome in trials for genetic eye disease such as Leber hereditary optic neuropathy.

Mackey DA, Kearns LS.Clin Exp Ophthalmol. 2019 Aug;47(6):704-705. doi: 10.1111/ceo.13586. No abstract available.PMID: 31397049IF 2.250

Eye injury registries – A systematic review.

Hoskin AK, Watson SL, Mackey DA, Agrawal R, Keay L.Injury. 2019 Nov;50(11):1839-1846. doi: 10.1016/j.injury.2019.07.019. Epub 2019 Jul 26. Review.PMID: 31378543IF 1.834

Use of trypan blue to assess lymphatic function following trabeculectomy.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 10. doi: 10.1111/ceo.13534. [Epub ahead of print]PMID: 31074572IF 2.250

Retinal capillary perfusion: Spatial and temporal heterogeneity.

Yu DY, Cringle SJ, Yu PK, Balaratnasingam C, Mehnert A, Sarunic MV, An D, Su EN.Prog Retin Eye Res. 2019 May;70:23-54. doi: 10.1016/j.preteyeres.2019.01.001. Epub 2019 Feb 13. Review.PMID: 30769149IF 11.768

Association between focal lamina cribrosa defects and optic disc haemorrhage in glaucoma.

Mistry V, An D, Barry CJ, House PH, Morgan WH.Br J Ophthalmol. 2019 Apr 25. pii: bjophthalmol-2018-313775. doi: 10.1136/bjophthalmol-2018-313775. [Epub ahead of print]PMID: 31023711IF 3.615

Association of Exercise and Swimming Goggles With Modulation of Cerebro-ocular Hemodynamics and Pressures in a Model of Spaceflight-Associated Neuro-ocular Syndrome.

Scott JM, Tucker WJ, Martin D, Crowell JB, Goetchius E, Ozgur O, Hamilton S, Otto C, Gonzales R, Ritter M, Newby N, DeWitt J, Stenger MB, Ploutz-Snyder R, Ploutz-Snyder L, Morgan WH, Haykowsky MJ.JAMA Ophthalmol. 2019 Apr 18. doi: 10.1001/jamaophthalmol.2019.0459. [Epub ahead of print]PMID: 30998818IF 6.167

Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.

Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA.Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17.PMID: 30659849IF 7.732

Comparison of Ophthalmic Medication Prices Between the United States and Australia.

Parikh R, Feng PW, Tainsh L, Sakurada Y, Balaratnasingam C, Khurana RN, Hemmati H, Modi YS.JAMA Ophthalmol. 2019 Jan 10. doi: 10.1001/jamaophthalmol.2018.6395. [Epub ahead of print] Erratum in:

JAMA Ophthalmol. 2019 May 9PMID: 30629105IF 6.167

Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis (IRVAN) in a Patient Without IRVAN History.

Balaratnasingam C, Yannuzzi LA, Franchina M, Freund KB.JAMA Ophthalmol. 2019 Feb 1;137(2): 230-232. doi: 10.1001/jamaophthalmol. 2018.5247. No abstract available.PMID: 30419083IF 6.167

Experimental Immunology

MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and is Influenced by the Microbiota.

Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, Hülsdünker J, Varelias A, Vetizou M, Kuns RD, Robb RJ, Zhang P, Blazar BR, Thomas R, Begun J, Waddell N, Trinchieri G, Zeiser R, Clouston AD, Degli-Esposti MA, Hill GR.Immunity. 2019 Nov 19;51(5):885-898.e7. doi: 10.1016/j.immuni.2019.08.011. Epub 2019 Sep 18.PMID: 31542340IF 21.522

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.

Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, Cursons J, Hennessy R, Hutchinson DS, Harrison C, Kita B, Vivier E, Webb AI, Degli-Esposti MA, Davis MJ, Huntington ND, Souza-Fonseca-Guimaraes F.Sci Signal. 2019 Aug 27;12(596). pii: eaat7527. doi: 10.1126/scisignal.aat7527.PMID: 31455725IF 6.565

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ.Sci Transl Med. 2019 Jul 17;11(501). pii: eaav7816. doi: 10.1126/scitranslmed.aav7816.PMID: 31316010IF 17.2

The Avidity Game: Selecting Natural-Born Killers.

Andoniou CE, Schuster IS, Degli-Esposti MA.Immunity. 2019 Jun 18;50(6):1337-1339. doi: 10.1016/j.immuni.2019.05.018.PMID: 31216454IF 21.522

Three-year follow-up of Phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age related macular degeneration.

Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ.Am J Ophthalmol. 2019 Mar 13. pii: S0002-9394(19)30104-7. doi: 10.1016/j.ajo.2019.03.006. [Epub ahead of print]PMID: 30878487IF 4.483

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation.

Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, Daly S, Varelias A, Tey SK, Degli-Esposti MA, Hill GR.Science. 2019 Jan 18;363(6424):288-293. doi: 10.1126/science.aat0066.PMID: 30655443IF 41.063

Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity.

Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, Yu T, McGinley AM, Quinn SM, Massilamany C, Reddy J, Forrester JV, Mills KH.EMBO Rep. 2019 May;20(5). pii: e47121. doi: 10.15252/embr.201847121. Epub 2019 Mar 20.PMID: 30894405IF 8.383

Transmission Electron Microscopy Data on drusen-like deposits in the retinal degeneration sTg-IRBP: HEL mouse model.

Liu YH, Mölzer C, Milne GC, Kuffová L, Forrester JV.Data Brief. 2018 Dec 6;22:140-144. doi: 10.1016/j.dib.2018.12.007. eCollection 2019 Feb.PMID: 30581918IF 0.970

Retinal Genomics and Therapy

Postmitotic Cone Migration Mechanisms in the Mammalian Retina.

Carvalho LS, Mellough CB.Adv Exp Med Biol. 2019;1185:489-493. doi: 10.1007/978-3-030-27378-1_80. Review.PMID: 31884659IF 2.126

The Role of the Voltage-Gated Potassium Channel Proteins Kv8.2 and Kv2.1 in Vision and Retinal Disease: Insights from the Study of Mouse Gene Knock-Out Mutations.

Hart NS, Mountford JK, Voigt V, Fuller-Carter P, Barth M, Nerbonne JM, Hunt DM, Carvalho LS.eNeuro. 2019 Feb 25;6(1). pii: ENEURO.0032-19.2019. doi: 10.1523/ENEURO.0032-19.2019. eCollection

2019 Jan-Feb.PMID: 30820446IF 3.46

Phototactic tails: Evolution and molecular basis of a novel sensory trait in sea snakes.Crowe-Riddell JM, Simões BF, Partridge JC, Hunt DM, Delean S, Schwerdt JG, Breen J, Ludington A, Gower DJ, Sanders KL.Mol Ecol. 2019 Apr;28(8):2013-2028. doi: 10.1111/mec.15022. Epub 2019 Feb 15.PMID: 30767303IF 5.855

Systematic Comparison of Retinal Organoid Differentiation from Human Pluripotent Stem Cells Reveals Stage Specific, Cell Line, and Methodological Differences.Mellough CB, Collin J, Queen R, Hilgen G, Dorgau B, Zerti D, Felemban M, White K, Sernagor E, Lako M.Stem Cells Transl Med. 2019 Jul;8(7): 694-706. doi: 10.1002/sctm.18-0267. Epub 2019 Mar 27.PMID: 30916455IF 5.962

An integrated transcriptional analysis of the developing human retina.Mellough CB, Bauer R, Collin J, Dorgau B, Zerti D, Dolan DWP, Jones CM, Izuogu OG, Yu M, Hallam D, Steyn JS, White K, Steel DH, Santibanez-Koref M, Elliott DJ, Jackson MS, Lindsay S, Grellscheid S, Lako M.Development. 2019 Jan 29;146(2). pii: dev169474. doi: 10.1242/dev.169474.PMID: 30696714IF 5.763

Lions Outback Vision

On-call telehealth for visiting optometry in regional Western Australia improves patient access to eye care.Nguyen AA, Baker A, Turner AW.Clin Exp Optom. 2019 Oct 23. doi: 10.1111/cxo.12979. [Epub ahead of print] No abstract available.PMID: 31646665IF 1.559

Evaluating the impact of the Lions Outback Vision mobile ophthalmology service.Fu S, Jeyaraj J, Turner AW.Clin Exp Ophthalmol. 2019 Apr 25. doi: 10.1111/ceo.13522. [Epub ahead of print] No abstract available.PMID: 31021477IF 2.250

Review of cataract surgery in rural north Western Australia with the Lions Outback Vision.McGlacken-Byrne A, Turner AW, Drinkwater J.Clin Exp Ophthalmol. 2019 Feb 22. doi: 10.1111/ceo.13481. [Epub ahead of print] No abstract available. PMID: 30801933IF 2.250

Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Drinkwater JJ, Davis TME, Turner AW, Bruce DG, Davis WA.Diabetes Care. 2019 Feb;42(2):288-296. doi: 10.2337/dc18-1556. Epub 2018 Dec 6.PMID: 30523034IF 15.270

Clinicians

Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial.

Mehta H, Lim LL, Nguyen V, Qatarneh D, Wickremasinghe SS, Hodgson LAB, Quin GJ, McAllister IL, Gillies MC, Fraser-Bell S.Ophthalmol Retina. 2019 Mar;3(3):286-287. doi: 10.1016/j.oret.2018.10.010. Epub 2018 Oct 25. No abstract available.PMID: 31014709IF 6.1

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL.JAMA Ophthalmol. 2019 Jan 24. doi: 10.1001/jamaophthalmol.2018.6776. [Epub ahead of print]PMID: 30676617 IF 6.167

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators.Ophthalmology. 2019 May;126(5):723-734. doi: 10.1016/j.ophtha.2018.11.025. Epub 2018 Nov 29.PMID: 30502372IF 7.732

Using the first-eye prediction error in cataract surgery to refine the refractive outcome of the second eye.

Turnbull AMJ, Barrett GD.J Cataract Refract Surg. 2019 Jul 17. pii: S0886-3350(19)30281-0. doi: 10.1016/j.jcrs.2019.04.008. [Epub ahead of print]PMID: 31326224IF 2.238

New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.

Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS.Semin Arthritis Rheum. 2019 Jun 10. pii: S0049-0172(18)30557-2. doi: 10.1016/j.

semarthrit.2019.06.004. [Epub ahead of print] Review.PMID: 31301816IF 5.072

Current ophthalmology practice patterns for syphilitic uveitis.

Oliver GF, Stathis RM, Furtado JM, Arantes TE, McCluskey PJ, Matthews JM; International Ocular Syphilis Study Group, Smith JR.Br J Ophthalmol. 2019 Jan 30. pii: bjophthalmol-2018-313207. doi: 10.1136/bjophthalmol-2018-313207. [Epub ahead of print]PMID: 31021330IF 3.615

Reduced expression of apolipoprotein E and immunoglobulin heavy constant gamma 1 proteins in Fuchs endothelial corneal dystrophy.

Kuot A, Ronci M, Mills R, Klebe S, Snibson G, Wiffen S, Loh R, Corbett M, Zhou T, Chataway T, Burdon KP, Craig JE, Urbani A, Sharma S.Clin Exp Ophthalmol. 2019 Jun 17. doi: 10.1111/ceo.13569. [Epub ahead of print] PMID: 31206232IF 2.250

Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.

Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group.Ophthalmology. 2019 Apr;126(4):540-549. doi: 10.1016/j.ophtha.2018.09.041. Epub 2018 Oct 4.PMID: 30292541IF 3.615

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.

Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group.Acta Ophthalmol. 2019 Nov;97(7): e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9.PMID: 30968592IF 3.152

2 3 4

Associations between Optic Disc Measures and Obstructive Sleep Apnea in Young Adults.Lee SSY, McArdle N, Sanfilippo PG, Yazar S, Eastwood PR, Hewitt AW, Li Q, Mackey DA.Ophthalmology. 2019 May 17. pii: S0161-6420(18)33221-4. doi: 10.1016/j.ophtha.2019.04.041. [Epub ahead of print]PMID: 31196726IF 7.732

Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology.Spracklen CN, Karaderi T, Yaghootkar H, Schurmann C, Fine RS, Kutalik Z, Preuss MH, Lu Y, Wittemans LBL, Adair LS, Allison M, Amin N, Auer PL, Bartz TM, Blüher M, Boehnke M, Borja JB, Bork-Jensen J, Broer L, Chasman DI, Chen YI, Chirstofidou P, Demirkan A, van Duijn CM, Feitosa MF, Garcia ME, Graff M, Grallert H, Grarup N, Guo X, Haesser J, Hansen T, Harris TB, Highland HM, Hong J, Ikram MA, Ingelsson E, Jackson R, Jousilahti P, Kähönen M, Kizer JR, Kovacs P, Kriebel J, Laakso M, Lange LA, Lehtimäki T, Li J, Li-Gao R, Lind L, Luan J, Lyytikäinen LP, MacGregor S, Mackey DA, Mahajan A, Mangino M, Männistö S, McCarthy MI, McKnight B, Medina-Gomez C, Meigs JB, Molnos S, Mook-Kanamori D, Morris AP, de Mutsert R, Nalls MA, Nedeljkovic I, North KE, Pennell CE, Pradhan AD, Province MA, Raitakari OT, Raulerson CK, Reiner AP, Ridker PM, Ripatti S, Roberston N, Rotter JI, Salomaa V, Sandoval-Zárate AA, Sitlani CM, Spector TD, Strauch K, Stumvoll M, Taylor KD, Thuesen B, Tönjes A, Uitterlinden AG, Venturini C, Walker M, Wang CA, Wang S, Wareham NJ, Willems SM, Willems van Dijk K, Wilson JG, Wu Y, Yao J, Young KL, Langenberg C, Frayling TM, Kilpeläinen TO, Lindgren CM, Loos RJF, Mohlke KL.Am J Hum Genet. 2019 Jul 3;105(1):15-28. doi: 10.1016/j.ajhg.2019.05.002. Epub 2019 Jun 6.PMID: 31178129 Erratum in: PMID: 31491410 IF 9.924

Publisher Correction: Genome-wide association meta-analysis of individuals of European ancestry identifies new loci explaining a substantial fraction of hair color variation and heritability.Hysi PG, Valdes AM, Liu F, Furlotte NA, Evans DM, Bataille V, Visconti A, Hemani G, McMahon G, Ring SM, Smith GD, Duffy DL, Zhu G, Gordon SD, Medland SE, Lin BD, Willemsen G, Jan Hottenga J, Vuckovic D, Girotto G, Gandin I, Sala C, Concas MP, Brumat M, Gasparini P, Toniolo D, Cocca M, Robino A, Yazar S, Hewitt AW, Chen Y, Zeng C, Uitterlinden AG, Ikram MA, Hamer MA, van Duijn CM, Nijsten T, Mackey DA, Falchi M, Boomsma DI, Martin NG; International Visible Trait Genetics Consortium, Hinds DA, Kayser M, Spector TD.Nat Genet. 2019 Jul;51(7):1190. doi: 10.1038/s41588-019-0446-3.PMID: 31150021IF 25.455

Seeing the impact of the Glaucoma Inheritance Study in Tasmania after 25 years.

Mackey DA, Craig JE, Hewitt AW.Clin Exp Ophthalmol. 2019 Jul;47(5):677-679. doi: 10.1111/ceo.13446. Epub 2018 Dec 18.PMID: 30467939IF 2.250

Mobile touch screen device use and associations with musculoskeletal symptoms and visual health in a nationally representative sample of Singaporean adolescents.

Toh SH, Coenen P, Howie EK, Mukherjee S, Mackey DA, Straker LM.Ergonomics. 2019 Jun;62(6):778-793. doi: 10.1080/00140139.2018.1562107. Epub 2019 Apr 23.PMID: 30575442IF 2.181

The Relationship Between Optic Disc Parameters and Female Reproductive Factors in Young Women.

Lee SSY, Yazar S, Pasquale LR, Sanfilippo PG, Hewitt AW, Hickey M, Skinner R, Mackey DA.Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):224-228. doi: 10.22608/APO.2018329. Epub 2018 Dec 31.PMID: 30596227IF 2.25

Repurposing blue laser autofluorescence to measure ocular sun exposure.

Lingham G, Burton A, Brown HA, Huynh E, Yazar S, Coroneo MT, Mackey DA.Clin Exp Ophthalmol. 2019 May;47(4):445-452. doi: 10.1111/ceo.13423. Epub 2018 Nov 14.PMID: 30345715IF 2.250

Genetic correlations between diabetes and glaucoma: an analysis of continuous and dichotomous phenotypes.

Laville V, Kang JH, Cousins CC, Iglesias AI, Nagy R, Cooke Bailey JN, Igo RP Jr, Song YE, Chasman DI, Christen WG, Kraft P, Rosner BA, Hu F, Wilson JF, Gharahkhani P, Hewitt AW, Mackey DA, Hysi PG, Hammond CJ, vanDuijn CM, Haines JL, Vitart V, Fingert JH, Hauser MA, Aschard H, Wiggs JL, Khawaja AP, MacGregor S, Pasquale LR; UK Biobank, International Glaucoma Genetics Consortium, NEIGHBORHOOD Consortium.Am J Ophthalmol. 2019 May 20. pii: S0002-9394(19)30245-4. doi: 10.1016/j.ajo.2019.05.015. [Epub ahead of print]PMID: 31121135IF 4.483

Differential stability of variant OPN1LW gene transcripts in myopic patients.

Mountford JK, Davies WIL, Griffiths LR, Yazar S, Mackey DA, Hunt DM.

Mol Vis. 2019 Mar 17;25:183-193. eCollection 2019.PMID: 30996587IF 2.174

Eye Injuries across history and the evolution of eye protection.

Hoskin AK, Mackey DA, Keay L, Agrawal R, Watson S.Acta Ophthalmol. 2019 Mar 25. doi: 10.1111/aos.14086. [Epub ahead of print]PMID: 30907494IF 3.152

IMI – Myopia Genetics Report.

Tedja MS, Haarman AEG, Meester-Smoor MA, Kaprio J, Mackey DA, Guggenheim JA, Hammond CJ, Verhoeven VJM, Klaver CCW; CREAM Consortium.Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M89-M105. doi: 10.1167/iovs. 18-25965.PMID: 30817828IF 3.812

Low 25-Hydroxyvitamin D Concentration Is Not Associated With Refractive Error in Middle-Aged and Older Western Australian Adults.

Lingham G, Yazar S, Lucas RM, Walsh JP, Zhu K, Hunter M, Lim EM, Cooke BR, Mackey DA.Transl Vis Sci Technol. 2019 Jan 22;8(1):13. doi: 10.1167/tvst.8.1.13. eCollection 2019 Jan.PMID: 30697464IF 2.399

Prevalence of FOXC1 Variants in Individuals With a Suspected Diagnosis of Primary Congenital Glaucoma.

Siggs OM, Souzeau E, Pasutto F, Dubowsky A, Smith JEH, Taranath D, Pater J, Rait JL, Narita A, Mauri L, Del Longo A, Reis A, Chappell A, Kearns LS, Staffieri SE, Elder JE, Ruddle JB, Hewitt AW, Burdon KP, Mackey DA, Craig JE.JAMA Ophthalmol. 2019 Jan 17. doi: 10.1001/jamaophthalmol.2018.5646. [Epub ahead of print] PMID: 30653210IF 6.167

Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW; Melanoma GWAS Consortium, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT,

Automatic choroidal segmentation in OCT images using supervised deep learning methods.Kugelman J, Alonso-Caneiro D, Read SA, Hamwood J, Vincent SJ, Chen FK, Collins MJ.Sci Rep. 2019 Sep 16;9(1):13298. doi: 10.1038/s41598-019-49816-4.PMID: 31527630

Generation of three induced pluripotent stem cell lines from an isolated inherited retinal dystrophy patient with RCBTB1 frameshifting mutations.

Huang Z, Zhang D, Chen SC, Thompson JA, McLaren T, Lamey T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Oct;40:101549. doi: 10.1016/j.scr.2019.101549. Epub 2019 Aug 23.PMID: 31494449IF 3.929

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.

Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD; Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group.Ophthalmology. 2019 Jun;126(6):829-838. doi: 10.1016/j.ophtha.2018.09.015. Epub 2018 Sep 20. PMID: 30244144IF 7.732

A computational framework to investigate retinal haemodynamics and tissue stress.

Rebhan J, Parker LP, Kelsey LJ, Chen FK, Doyle BJ.Biomech Model Mechanobiol. 2019 May 28. doi: 10.1007/s10237-019-01172-y. [Epub ahead of print]PMID: 31140054IF 2.829

Generation of an induced pluripotent stem cell line from a patient with retinitis pigmentosa caused by RP1 mutation.

Zhang X, Moon SY, Zhang D, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Apr 25;37:101452. doi: 10.1016/j.scr.2019.101452. [Epub ahead of print]PMID: 31059986IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with compound heterozygous mutations in the USH2A gene.

McLenachan S, Wong EYM, Zhang X, Leith F, Moon SY, Zhang D, Chen SC, Thompson

JA, McLaren T, Lamey T, De Roach JN, Atlas MD, Dilley RJ, Chen FK.Stem Cell Res. 2019 Apr;36:101420. doi: 10.1016/j.scr.2019.101420. Epub 2019 Mar 16.PMID: 30904819 IF 3.929

ENDOGENOUS ENDOPHTHALMITIS IN WESTERN AUSTRALIA: A Sixteen-Year Retrospective Study.

Gounder PA, Hille DM, Khoo YJ, Phagura RS, Chen FK.Retina. 2019 Mar 12. doi: 10.1097/IAE.0000000000002512. [Epub ahead of print]PMID: 30893275IF 3.08

Near-infrared spectroscopy parameters in patients undergoing continuous venovenous hemodiafiltration.

Chaves RCF, Tafner PFDA, Chen FK, Meneghini LB, Corrêa TD, Rabello Filho R, Cendoroglo Neto M, Santos OFPD, Serpa Neto A.Einstein (Sao Paulo). 2019 Feb 14;17(1):eAO4439. doi: 10.31744/einstein_journal/2019AO4439. English, Portuguese.PMID: 30785493 IF 0.11

Generation of the induced pluripotent stem cell line from a patient with autosomal recessive ABCA4-mediated Stargardt Macular Dystrophy.

Claassen JN, Zhang D, Chen SC, Moon SY, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Jan;34:101352. doi: 10.1016/j.scr.2018.11.013. Epub 2018 Nov 30.PMID: 30634128IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with dominant PRPF31 mutation and a related non-penetrant carrier.

McLenachan S, Zhang D, Zhang X, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, Fletcher S, Chen FK.Stem Cell Res. 2019 Jan;34:101357. doi: 10. 1016/j.scr.2018.11.018. Epub 2018 Dec 10.PMID:30611018IF 3.929

Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).

Chen FK, Zhang X, Eintracht J, Zhang D, Arunachalam S, Thompson JA, Chelva E, Mallon D, Chen SC, McLaren T, Lamey T, De Roach J, McLenachan S.Doc Ophthalmol. 2019 Feb;138(1):55-70. doi: 10.1007/s10633-018-9665-7. Epub 2018 Nov 16. PMID: 30446867IF 1.460

BRANCH RETINAL VEIN OCCLUSION SECONDARY TO A RETINAL ARTERIOLAR MACROANEURYSM: A NOVEL MECHANISM SUPPORTED BY MULTIMODAL IMAGING.

Chen Y, Chen SDM, Chen FK.Retin Cases Brief Rep. 2019 Winter;13(1):10-14. doi: 10.1097/ICB.0000000000000517. PMID: 28079651IF 0.79

Physiology and Pharmacology

XEN Gel Stent to Treat ICE Syndrome: 4 Cases.

Lin MM, Morgan WH, Kolomeyer NN, Moster SJ, Zheng CX, Giubilato A, Moster MR.J Glaucoma. 2019 Dec;28(12):1090-1094. doi: 10.1097/IJG.0000000000001341.PMID: 31425336IF 1.661

Topographic Distribution of Contractile Protein in the Human Macular Microvasculature.

Yu PK, An D, Balaratnasingam C, Cringle SJ, Yu DY.Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4574-4582. doi: 10.1167/iovs. 19-26986.PMID: 31675074IF 3.812

The Nature and Frequency of Outer Retinal Disruption in Idiopathic Multifocal Choroiditis Associated With Persistent Fundus Hyperautofluorescence.

Kaden TR, Gattoussi S, Dolz-Marco R, Balaratnasingam C, Yannuzzi LA, Freund KB.Ophthalmic Surg Lasers Imaging Retina. 2019 Nov 1;50(11):675-683. doi: 10.3928/23258160-20191031-02.PMID: 31755966IF 1.422

Correlation between Histologic and OCT Angiography Analysis of Macular Circulation.

Balaratnasingam C, An D, Freund KB, Francke A, Yu DY.Ophthalmology. 2019 May 23. pii: S0161-6420(19)30795-X. doi: 10.1016/j.ophtha.2019.05.022. [Epub ahead of print] No abstract available.PMID: 31227322IF 7.732

Use of trypan blue as an aqueous tracer dye to investigate hypotony where cyclodialysis cleft is suspected.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 15. doi: 10.1111/ceo.13558. [Epub ahead of print]PMID: 31090997IF 2.250

Bataille V, Falchi M, Han J, Martin NG.Nat Commun. 2019 Jan 14;10(1):299. doi: 10.1038/s41467-018-08078-w. PMID: 30643134IF 11.878

Author Correction: Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Iglesias AI, Mishra A, Vitart V, Bykhovskaya Y, Höhn R, Springelkamp H, Cuellar-Partida G, Gharahkhani P, Bailey JNC, Willoughby CE, Li X, Yazar S, Nag A, Khawaja AP, Polašek O, Siscovick D, Mitchell P, Tham YC, Haines JL, Kearns LS, Hayward C, Shi Y, van Leeuwen EM, Taylor KD; Blue Mountains Eye Study – GWAS group, Bonnemaijer P, Rotter JI, Martin NG, Zeller T, Mills RA, Souzeau E, Staffieri SE, Jonas JB, Schmidtmann I, Boutin T, Kang JH, Lucas SEM, Wong TY, Beutel ME, Wilson JF; Wellcome Trust Case Control Consortium 2 (WTCCC2); NEIGHBORHOOD consortium, Uitterlinden AG, Vithana EN, Foster PJ, Hysi PG, Hewitt AW, Khor CC, Pasquale LR, Montgomery GW, Klaver CCW, Aung T, Pfeiffer N, Mackey DA, Hammond CJ, Cheng CY, Craig JE, Rabinowitz YS, Wiggs JL, Burdon KP, van Duijn CM, MacGregor S.Nat Commun. 2019 Jan 8;10(1):155. doi: 10.1038/s41467-018-07819-1. PMID: 30622277IF 11.878

Vitamin D and its pathway genes in myopia: systematic review and meta-analysis.

Tang SM, Lau T, Rong SS, Yazar S, Chen LJ, Mackey DA, Lucas RM, Pang CP, Yam JC.Br J Ophthalmol. 2019 Jan;103(1):8-17. doi: 10.1136/bjophthalmol-2018-312159. Epub 2018 Jul 17. PMID: 30018147IF 3.615

Current state and future prospects of artificial intelligence in ophthalmology: a review.

Hogarty DT, Mackey DA, Hewitt AW.Clin Exp Ophthalmol. 2019 Jan;47(1): 128-139. doi: 10.1111/ceo.13381. Epub 2018 Sep 30.PMID: 30155978IF 2.250

Traumatic hyphaema in children: a retrospective and prospective study of outcomes at an Australian paediatric centre.

Richards MD, Barnes K, Yardley AE, Hanman K, Lam GC, Mackey DA.BMJ Open Ophthalmol. 2019 Jan 30;4(1):e000215. doi: 10.1136/bmjophth-2018-000215. eCollection 2019.PMID: 31179388

Ocular Tissue Engineering Lab

Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in Age-Related Macular Degeneration.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Tindill N, Aung KZ, McGuinness MB, Makeyeva G, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Guymer RH.Ophthalmol Retina. 2019 Dec 16. pii: S2468-6530(19)30675-X. doi: 10.1016/j.oret.2019.12.011. [Epub ahead of print]PMID: 32088159IF 6.1

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK.Lung Cancer. 2020 Feb;140:87-92. doi: 10.1016/j.lungcan.2019.12.018. Epub 2019 Dec 31.PMID: 31901768IF 4.599

Analysis of the ABCA4 c.[2588G>C; 5603A>T] Allele in the Australian Population.

Thompson JA, Chiang JP, De Roach JN, McLaren TL, Chen FK, Hoffmann L, Campbell I, Lamey TM.Adv Exp Med Biol. 2019;1185:269-273. doi: 10.1007/978-3-030-27378-1_44.PMID: 31884623IF 2.126

Assessing the Use of Incorrectly Scaled Optical Coherence Tomography Angiography Images in Peer-Reviewed Studies: A Systematic Review.

Llanas S, Linderman RE, Chen FK, Carroll J.JAMA Ophthalmol. 2019 Nov 27. doi: 10.1001/jamaophthalmol.2019.4821. [Epub ahead of print]PMID: 31774456 IF 6.167

Reply.

Guymer RH, Wu Z, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Luu CD; LEAD Study Group.Ophthalmology. 2019 Dec;126(12):e92-e93. doi: 10.1016/j.ophtha.2019.07.017. No abstract available.PMID: 31759505IF 7.732

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision.

Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, Warrier SK, Stark AL, Rolfe OJ, Palmer JM, Hayward NK.Transl Vis Sci Technol. 2019 Nov 14;8(6):12. doi: 10.1167/tvst.8.6.12. eCollection 2019 Nov.PMID: 31737436IF 2.399

Automatic Detection of Cone Photoreceptors With Fully Convolutional Networks.

Hamwood J, Alonso-Caneiro D, Sampson DM, Collins MJ, Chen FK.Transl Vis Sci Technol. 2019 Nov 12;8(6):10. doi: 10.1167/tvst.8.6.10. eCollection 2019 Nov.PMID: 31737434IF 2.399

Clinical validation of the RTVue optical coherence tomography angiography image quality indicators.

Ali N, Sampson DM, Au Yong A, Jeewa R, Rajgopal S, Dutt DDCS, Mohamed S, Mohamed S, Menghini M, Hansen A, Chen FK.Clin Exp Ophthalmol. 2019 Nov 9. doi: 10.1111/ceo.13680. [Epub ahead of print]PMID: 31705836IF 2.250

Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration.

McGuinness MB, Finger RP, Wu Z, Luu CD, Chen FK, Arnold JJ, Chakravarthy U, Heriot WJ, Runciman J, Guymer RH; LEAD Study Group.Transl Vis Sci Technol. 2019 Sep 11;8(5):3. doi: 10.1167/tvst.8.5.3. eCollection 2019 Sep.PMID: 31588369IF 2.399

Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, Harper CA, Wickremasinghe SS, Sandhu SS, McGuinness MB, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Wintergerst MWM, Gorgi Zadeh S, Schultz T, Finger RP, Cohn AC, Baglin EK, Sharangan P, Guymer RH; LEAD Study Group.Ophthalmol Retina. 2019 Dec;3(12):1026-1034. doi: 10.1016/j.oret.2019.07.008. Epub 2019 Jul 22.PMID: 31582304 IF 6.1

Optimization of silk fibroin membranes for retinal implantation.

Suzuki S, Shadforth AMA, McLenachan S, Zhang D, Chen SC, Walshe J, Lidgerwood GE, Pébay A, Chirila TV, Chen FK, Harkin DG.Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110131. doi: 10.1016/j.msec.2019.110131. Epub 2019 Aug 29. PMID: 31546376 IF 4.959

2 3 4

Associations between Optic Disc Measures and Obstructive Sleep Apnea in Young Adults.Lee SSY, McArdle N, Sanfilippo PG, Yazar S, Eastwood PR, Hewitt AW, Li Q, Mackey DA.Ophthalmology. 2019 May 17. pii: S0161-6420(18)33221-4. doi: 10.1016/j.ophtha.2019.04.041. [Epub ahead of print]PMID: 31196726IF 7.732

Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology.Spracklen CN, Karaderi T, Yaghootkar H, Schurmann C, Fine RS, Kutalik Z, Preuss MH, Lu Y, Wittemans LBL, Adair LS, Allison M, Amin N, Auer PL, Bartz TM, Blüher M, Boehnke M, Borja JB, Bork-Jensen J, Broer L, Chasman DI, Chen YI, Chirstofidou P, Demirkan A, van Duijn CM, Feitosa MF, Garcia ME, Graff M, Grallert H, Grarup N, Guo X, Haesser J, Hansen T, Harris TB, Highland HM, Hong J, Ikram MA, Ingelsson E, Jackson R, Jousilahti P, Kähönen M, Kizer JR, Kovacs P, Kriebel J, Laakso M, Lange LA, Lehtimäki T, Li J, Li-Gao R, Lind L, Luan J, Lyytikäinen LP, MacGregor S, Mackey DA, Mahajan A, Mangino M, Männistö S, McCarthy MI, McKnight B, Medina-Gomez C, Meigs JB, Molnos S, Mook-Kanamori D, Morris AP, de Mutsert R, Nalls MA, Nedeljkovic I, North KE, Pennell CE, Pradhan AD, Province MA, Raitakari OT, Raulerson CK, Reiner AP, Ridker PM, Ripatti S, Roberston N, Rotter JI, Salomaa V, Sandoval-Zárate AA, Sitlani CM, Spector TD, Strauch K, Stumvoll M, Taylor KD, Thuesen B, Tönjes A, Uitterlinden AG, Venturini C, Walker M, Wang CA, Wang S, Wareham NJ, Willems SM, Willems van Dijk K, Wilson JG, Wu Y, Yao J, Young KL, Langenberg C, Frayling TM, Kilpeläinen TO, Lindgren CM, Loos RJF, Mohlke KL.Am J Hum Genet. 2019 Jul 3;105(1):15-28. doi: 10.1016/j.ajhg.2019.05.002. Epub 2019 Jun 6.PMID: 31178129 Erratum in: PMID: 31491410 IF 9.924

Publisher Correction: Genome-wide association meta-analysis of individuals of European ancestry identifies new loci explaining a substantial fraction of hair color variation and heritability.Hysi PG, Valdes AM, Liu F, Furlotte NA, Evans DM, Bataille V, Visconti A, Hemani G, McMahon G, Ring SM, Smith GD, Duffy DL, Zhu G, Gordon SD, Medland SE, Lin BD, Willemsen G, Jan Hottenga J, Vuckovic D, Girotto G, Gandin I, Sala C, Concas MP, Brumat M, Gasparini P, Toniolo D, Cocca M, Robino A, Yazar S, Hewitt AW, Chen Y, Zeng C, Uitterlinden AG, Ikram MA, Hamer MA, van Duijn CM, Nijsten T, Mackey DA, Falchi M, Boomsma DI, Martin NG; International Visible Trait Genetics Consortium, Hinds DA, Kayser M, Spector TD.Nat Genet. 2019 Jul;51(7):1190. doi: 10.1038/s41588-019-0446-3.PMID: 31150021IF 25.455

Seeing the impact of the Glaucoma Inheritance Study in Tasmania after 25 years.

Mackey DA, Craig JE, Hewitt AW.Clin Exp Ophthalmol. 2019 Jul;47(5):677-679. doi: 10.1111/ceo.13446. Epub 2018 Dec 18.PMID: 30467939IF 2.250

Mobile touch screen device use and associations with musculoskeletal symptoms and visual health in a nationally representative sample of Singaporean adolescents.

Toh SH, Coenen P, Howie EK, Mukherjee S, Mackey DA, Straker LM.Ergonomics. 2019 Jun;62(6):778-793. doi: 10.1080/00140139.2018.1562107. Epub 2019 Apr 23.PMID: 30575442IF 2.181

The Relationship Between Optic Disc Parameters and Female Reproductive Factors in Young Women.

Lee SSY, Yazar S, Pasquale LR, Sanfilippo PG, Hewitt AW, Hickey M, Skinner R, Mackey DA.Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):224-228. doi: 10.22608/APO.2018329. Epub 2018 Dec 31.PMID: 30596227IF 2.25

Repurposing blue laser autofluorescence to measure ocular sun exposure.

Lingham G, Burton A, Brown HA, Huynh E, Yazar S, Coroneo MT, Mackey DA.Clin Exp Ophthalmol. 2019 May;47(4):445-452. doi: 10.1111/ceo.13423. Epub 2018 Nov 14.PMID: 30345715IF 2.250

Genetic correlations between diabetes and glaucoma: an analysis of continuous and dichotomous phenotypes.

Laville V, Kang JH, Cousins CC, Iglesias AI, Nagy R, Cooke Bailey JN, Igo RP Jr, Song YE, Chasman DI, Christen WG, Kraft P, Rosner BA, Hu F, Wilson JF, Gharahkhani P, Hewitt AW, Mackey DA, Hysi PG, Hammond CJ, vanDuijn CM, Haines JL, Vitart V, Fingert JH, Hauser MA, Aschard H, Wiggs JL, Khawaja AP, MacGregor S, Pasquale LR; UK Biobank, International Glaucoma Genetics Consortium, NEIGHBORHOOD Consortium.Am J Ophthalmol. 2019 May 20. pii: S0002-9394(19)30245-4. doi: 10.1016/j.ajo.2019.05.015. [Epub ahead of print]PMID: 31121135IF 4.483

Differential stability of variant OPN1LW gene transcripts in myopic patients.

Mountford JK, Davies WIL, Griffiths LR, Yazar S, Mackey DA, Hunt DM.

Mol Vis. 2019 Mar 17;25:183-193. eCollection 2019.PMID: 30996587IF 2.174

Eye Injuries across history and the evolution of eye protection.

Hoskin AK, Mackey DA, Keay L, Agrawal R, Watson S.Acta Ophthalmol. 2019 Mar 25. doi: 10.1111/aos.14086. [Epub ahead of print]PMID: 30907494IF 3.152

IMI – Myopia Genetics Report.

Tedja MS, Haarman AEG, Meester-Smoor MA, Kaprio J, Mackey DA, Guggenheim JA, Hammond CJ, Verhoeven VJM, Klaver CCW; CREAM Consortium.Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M89-M105. doi: 10.1167/iovs. 18-25965.PMID: 30817828IF 3.812

Low 25-Hydroxyvitamin D Concentration Is Not Associated With Refractive Error in Middle-Aged and Older Western Australian Adults.

Lingham G, Yazar S, Lucas RM, Walsh JP, Zhu K, Hunter M, Lim EM, Cooke BR, Mackey DA.Transl Vis Sci Technol. 2019 Jan 22;8(1):13. doi: 10.1167/tvst.8.1.13. eCollection 2019 Jan.PMID: 30697464IF 2.399

Prevalence of FOXC1 Variants in Individuals With a Suspected Diagnosis of Primary Congenital Glaucoma.

Siggs OM, Souzeau E, Pasutto F, Dubowsky A, Smith JEH, Taranath D, Pater J, Rait JL, Narita A, Mauri L, Del Longo A, Reis A, Chappell A, Kearns LS, Staffieri SE, Elder JE, Ruddle JB, Hewitt AW, Burdon KP, Mackey DA, Craig JE.JAMA Ophthalmol. 2019 Jan 17. doi: 10.1001/jamaophthalmol.2018.5646. [Epub ahead of print] PMID: 30653210IF 6.167

Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW; Melanoma GWAS Consortium, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT,

Automatic choroidal segmentation in OCT images using supervised deep learning methods.Kugelman J, Alonso-Caneiro D, Read SA, Hamwood J, Vincent SJ, Chen FK, Collins MJ.Sci Rep. 2019 Sep 16;9(1):13298. doi: 10.1038/s41598-019-49816-4.PMID: 31527630

Generation of three induced pluripotent stem cell lines from an isolated inherited retinal dystrophy patient with RCBTB1 frameshifting mutations.

Huang Z, Zhang D, Chen SC, Thompson JA, McLaren T, Lamey T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Oct;40:101549. doi: 10.1016/j.scr.2019.101549. Epub 2019 Aug 23.PMID: 31494449IF 3.929

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.

Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD; Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group.Ophthalmology. 2019 Jun;126(6):829-838. doi: 10.1016/j.ophtha.2018.09.015. Epub 2018 Sep 20. PMID: 30244144IF 7.732

A computational framework to investigate retinal haemodynamics and tissue stress.

Rebhan J, Parker LP, Kelsey LJ, Chen FK, Doyle BJ.Biomech Model Mechanobiol. 2019 May 28. doi: 10.1007/s10237-019-01172-y. [Epub ahead of print]PMID: 31140054IF 2.829

Generation of an induced pluripotent stem cell line from a patient with retinitis pigmentosa caused by RP1 mutation.

Zhang X, Moon SY, Zhang D, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Apr 25;37:101452. doi: 10.1016/j.scr.2019.101452. [Epub ahead of print]PMID: 31059986IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with compound heterozygous mutations in the USH2A gene.

McLenachan S, Wong EYM, Zhang X, Leith F, Moon SY, Zhang D, Chen SC, Thompson

JA, McLaren T, Lamey T, De Roach JN, Atlas MD, Dilley RJ, Chen FK.Stem Cell Res. 2019 Apr;36:101420. doi: 10.1016/j.scr.2019.101420. Epub 2019 Mar 16.PMID: 30904819 IF 3.929

ENDOGENOUS ENDOPHTHALMITIS IN WESTERN AUSTRALIA: A Sixteen-Year Retrospective Study.

Gounder PA, Hille DM, Khoo YJ, Phagura RS, Chen FK.Retina. 2019 Mar 12. doi: 10.1097/IAE.0000000000002512. [Epub ahead of print]PMID: 30893275IF 3.08

Near-infrared spectroscopy parameters in patients undergoing continuous venovenous hemodiafiltration.

Chaves RCF, Tafner PFDA, Chen FK, Meneghini LB, Corrêa TD, Rabello Filho R, Cendoroglo Neto M, Santos OFPD, Serpa Neto A.Einstein (Sao Paulo). 2019 Feb 14;17(1):eAO4439. doi: 10.31744/einstein_journal/2019AO4439. English, Portuguese.PMID: 30785493 IF 0.11

Generation of the induced pluripotent stem cell line from a patient with autosomal recessive ABCA4-mediated Stargardt Macular Dystrophy.

Claassen JN, Zhang D, Chen SC, Moon SY, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Jan;34:101352. doi: 10.1016/j.scr.2018.11.013. Epub 2018 Nov 30.PMID: 30634128IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with dominant PRPF31 mutation and a related non-penetrant carrier.

McLenachan S, Zhang D, Zhang X, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, Fletcher S, Chen FK.Stem Cell Res. 2019 Jan;34:101357. doi: 10. 1016/j.scr.2018.11.018. Epub 2018 Dec 10.PMID:30611018IF 3.929

Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).

Chen FK, Zhang X, Eintracht J, Zhang D, Arunachalam S, Thompson JA, Chelva E, Mallon D, Chen SC, McLaren T, Lamey T, De Roach J, McLenachan S.Doc Ophthalmol. 2019 Feb;138(1):55-70. doi: 10.1007/s10633-018-9665-7. Epub 2018 Nov 16. PMID: 30446867IF 1.460

BRANCH RETINAL VEIN OCCLUSION SECONDARY TO A RETINAL ARTERIOLAR MACROANEURYSM: A NOVEL MECHANISM SUPPORTED BY MULTIMODAL IMAGING.

Chen Y, Chen SDM, Chen FK.Retin Cases Brief Rep. 2019 Winter;13(1):10-14. doi: 10.1097/ICB.0000000000000517. PMID: 28079651IF 0.79

Physiology and Pharmacology

XEN Gel Stent to Treat ICE Syndrome: 4 Cases.

Lin MM, Morgan WH, Kolomeyer NN, Moster SJ, Zheng CX, Giubilato A, Moster MR.J Glaucoma. 2019 Dec;28(12):1090-1094. doi: 10.1097/IJG.0000000000001341.PMID: 31425336IF 1.661

Topographic Distribution of Contractile Protein in the Human Macular Microvasculature.

Yu PK, An D, Balaratnasingam C, Cringle SJ, Yu DY.Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4574-4582. doi: 10.1167/iovs. 19-26986.PMID: 31675074IF 3.812

The Nature and Frequency of Outer Retinal Disruption in Idiopathic Multifocal Choroiditis Associated With Persistent Fundus Hyperautofluorescence.

Kaden TR, Gattoussi S, Dolz-Marco R, Balaratnasingam C, Yannuzzi LA, Freund KB.Ophthalmic Surg Lasers Imaging Retina. 2019 Nov 1;50(11):675-683. doi: 10.3928/23258160-20191031-02.PMID: 31755966IF 1.422

Correlation between Histologic and OCT Angiography Analysis of Macular Circulation.

Balaratnasingam C, An D, Freund KB, Francke A, Yu DY.Ophthalmology. 2019 May 23. pii: S0161-6420(19)30795-X. doi: 10.1016/j.ophtha.2019.05.022. [Epub ahead of print] No abstract available.PMID: 31227322IF 7.732

Use of trypan blue as an aqueous tracer dye to investigate hypotony where cyclodialysis cleft is suspected.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 15. doi: 10.1111/ceo.13558. [Epub ahead of print]PMID: 31090997IF 2.250

Bataille V, Falchi M, Han J, Martin NG.Nat Commun. 2019 Jan 14;10(1):299. doi: 10.1038/s41467-018-08078-w. PMID: 30643134IF 11.878

Author Correction: Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Iglesias AI, Mishra A, Vitart V, Bykhovskaya Y, Höhn R, Springelkamp H, Cuellar-Partida G, Gharahkhani P, Bailey JNC, Willoughby CE, Li X, Yazar S, Nag A, Khawaja AP, Polašek O, Siscovick D, Mitchell P, Tham YC, Haines JL, Kearns LS, Hayward C, Shi Y, van Leeuwen EM, Taylor KD; Blue Mountains Eye Study – GWAS group, Bonnemaijer P, Rotter JI, Martin NG, Zeller T, Mills RA, Souzeau E, Staffieri SE, Jonas JB, Schmidtmann I, Boutin T, Kang JH, Lucas SEM, Wong TY, Beutel ME, Wilson JF; Wellcome Trust Case Control Consortium 2 (WTCCC2); NEIGHBORHOOD consortium, Uitterlinden AG, Vithana EN, Foster PJ, Hysi PG, Hewitt AW, Khor CC, Pasquale LR, Montgomery GW, Klaver CCW, Aung T, Pfeiffer N, Mackey DA, Hammond CJ, Cheng CY, Craig JE, Rabinowitz YS, Wiggs JL, Burdon KP, van Duijn CM, MacGregor S.Nat Commun. 2019 Jan 8;10(1):155. doi: 10.1038/s41467-018-07819-1. PMID: 30622277IF 11.878

Vitamin D and its pathway genes in myopia: systematic review and meta-analysis.

Tang SM, Lau T, Rong SS, Yazar S, Chen LJ, Mackey DA, Lucas RM, Pang CP, Yam JC.Br J Ophthalmol. 2019 Jan;103(1):8-17. doi: 10.1136/bjophthalmol-2018-312159. Epub 2018 Jul 17. PMID: 30018147IF 3.615

Current state and future prospects of artificial intelligence in ophthalmology: a review.

Hogarty DT, Mackey DA, Hewitt AW.Clin Exp Ophthalmol. 2019 Jan;47(1): 128-139. doi: 10.1111/ceo.13381. Epub 2018 Sep 30.PMID: 30155978IF 2.250

Traumatic hyphaema in children: a retrospective and prospective study of outcomes at an Australian paediatric centre.

Richards MD, Barnes K, Yardley AE, Hanman K, Lam GC, Mackey DA.BMJ Open Ophthalmol. 2019 Jan 30;4(1):e000215. doi: 10.1136/bmjophth-2018-000215. eCollection 2019.PMID: 31179388

Ocular Tissue Engineering Lab

Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in Age-Related Macular Degeneration.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Tindill N, Aung KZ, McGuinness MB, Makeyeva G, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Guymer RH.Ophthalmol Retina. 2019 Dec 16. pii: S2468-6530(19)30675-X. doi: 10.1016/j.oret.2019.12.011. [Epub ahead of print]PMID: 32088159IF 6.1

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK.Lung Cancer. 2020 Feb;140:87-92. doi: 10.1016/j.lungcan.2019.12.018. Epub 2019 Dec 31.PMID: 31901768IF 4.599

Analysis of the ABCA4 c.[2588G>C; 5603A>T] Allele in the Australian Population.

Thompson JA, Chiang JP, De Roach JN, McLaren TL, Chen FK, Hoffmann L, Campbell I, Lamey TM.Adv Exp Med Biol. 2019;1185:269-273. doi: 10.1007/978-3-030-27378-1_44.PMID: 31884623IF 2.126

Assessing the Use of Incorrectly Scaled Optical Coherence Tomography Angiography Images in Peer-Reviewed Studies: A Systematic Review.

Llanas S, Linderman RE, Chen FK, Carroll J.JAMA Ophthalmol. 2019 Nov 27. doi: 10.1001/jamaophthalmol.2019.4821. [Epub ahead of print]PMID: 31774456 IF 6.167

Reply.

Guymer RH, Wu Z, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Luu CD; LEAD Study Group.Ophthalmology. 2019 Dec;126(12):e92-e93. doi: 10.1016/j.ophtha.2019.07.017. No abstract available.PMID: 31759505IF 7.732

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision.

Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, Warrier SK, Stark AL, Rolfe OJ, Palmer JM, Hayward NK.Transl Vis Sci Technol. 2019 Nov 14;8(6):12. doi: 10.1167/tvst.8.6.12. eCollection 2019 Nov.PMID: 31737436IF 2.399

Automatic Detection of Cone Photoreceptors With Fully Convolutional Networks.

Hamwood J, Alonso-Caneiro D, Sampson DM, Collins MJ, Chen FK.Transl Vis Sci Technol. 2019 Nov 12;8(6):10. doi: 10.1167/tvst.8.6.10. eCollection 2019 Nov.PMID: 31737434IF 2.399

Clinical validation of the RTVue optical coherence tomography angiography image quality indicators.

Ali N, Sampson DM, Au Yong A, Jeewa R, Rajgopal S, Dutt DDCS, Mohamed S, Mohamed S, Menghini M, Hansen A, Chen FK.Clin Exp Ophthalmol. 2019 Nov 9. doi: 10.1111/ceo.13680. [Epub ahead of print]PMID: 31705836IF 2.250

Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration.

McGuinness MB, Finger RP, Wu Z, Luu CD, Chen FK, Arnold JJ, Chakravarthy U, Heriot WJ, Runciman J, Guymer RH; LEAD Study Group.Transl Vis Sci Technol. 2019 Sep 11;8(5):3. doi: 10.1167/tvst.8.5.3. eCollection 2019 Sep.PMID: 31588369IF 2.399

Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, Harper CA, Wickremasinghe SS, Sandhu SS, McGuinness MB, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Wintergerst MWM, Gorgi Zadeh S, Schultz T, Finger RP, Cohn AC, Baglin EK, Sharangan P, Guymer RH; LEAD Study Group.Ophthalmol Retina. 2019 Dec;3(12):1026-1034. doi: 10.1016/j.oret.2019.07.008. Epub 2019 Jul 22.PMID: 31582304 IF 6.1

Optimization of silk fibroin membranes for retinal implantation.

Suzuki S, Shadforth AMA, McLenachan S, Zhang D, Chen SC, Walshe J, Lidgerwood GE, Pébay A, Chirila TV, Chen FK, Harkin DG.Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110131. doi: 10.1016/j.msec.2019.110131. Epub 2019 Aug 29. PMID: 31546376 IF 4.959

2 3 4

Associations between Optic Disc Measures and Obstructive Sleep Apnea in Young Adults.Lee SSY, McArdle N, Sanfilippo PG, Yazar S, Eastwood PR, Hewitt AW, Li Q, Mackey DA.Ophthalmology. 2019 May 17. pii: S0161-6420(18)33221-4. doi: 10.1016/j.ophtha.2019.04.041. [Epub ahead of print]PMID: 31196726IF 7.732

Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology.Spracklen CN, Karaderi T, Yaghootkar H, Schurmann C, Fine RS, Kutalik Z, Preuss MH, Lu Y, Wittemans LBL, Adair LS, Allison M, Amin N, Auer PL, Bartz TM, Blüher M, Boehnke M, Borja JB, Bork-Jensen J, Broer L, Chasman DI, Chen YI, Chirstofidou P, Demirkan A, van Duijn CM, Feitosa MF, Garcia ME, Graff M, Grallert H, Grarup N, Guo X, Haesser J, Hansen T, Harris TB, Highland HM, Hong J, Ikram MA, Ingelsson E, Jackson R, Jousilahti P, Kähönen M, Kizer JR, Kovacs P, Kriebel J, Laakso M, Lange LA, Lehtimäki T, Li J, Li-Gao R, Lind L, Luan J, Lyytikäinen LP, MacGregor S, Mackey DA, Mahajan A, Mangino M, Männistö S, McCarthy MI, McKnight B, Medina-Gomez C, Meigs JB, Molnos S, Mook-Kanamori D, Morris AP, de Mutsert R, Nalls MA, Nedeljkovic I, North KE, Pennell CE, Pradhan AD, Province MA, Raitakari OT, Raulerson CK, Reiner AP, Ridker PM, Ripatti S, Roberston N, Rotter JI, Salomaa V, Sandoval-Zárate AA, Sitlani CM, Spector TD, Strauch K, Stumvoll M, Taylor KD, Thuesen B, Tönjes A, Uitterlinden AG, Venturini C, Walker M, Wang CA, Wang S, Wareham NJ, Willems SM, Willems van Dijk K, Wilson JG, Wu Y, Yao J, Young KL, Langenberg C, Frayling TM, Kilpeläinen TO, Lindgren CM, Loos RJF, Mohlke KL.Am J Hum Genet. 2019 Jul 3;105(1):15-28. doi: 10.1016/j.ajhg.2019.05.002. Epub 2019 Jun 6.PMID: 31178129 Erratum in: PMID: 31491410 IF 9.924

Publisher Correction: Genome-wide association meta-analysis of individuals of European ancestry identifies new loci explaining a substantial fraction of hair color variation and heritability.Hysi PG, Valdes AM, Liu F, Furlotte NA, Evans DM, Bataille V, Visconti A, Hemani G, McMahon G, Ring SM, Smith GD, Duffy DL, Zhu G, Gordon SD, Medland SE, Lin BD, Willemsen G, Jan Hottenga J, Vuckovic D, Girotto G, Gandin I, Sala C, Concas MP, Brumat M, Gasparini P, Toniolo D, Cocca M, Robino A, Yazar S, Hewitt AW, Chen Y, Zeng C, Uitterlinden AG, Ikram MA, Hamer MA, van Duijn CM, Nijsten T, Mackey DA, Falchi M, Boomsma DI, Martin NG; International Visible Trait Genetics Consortium, Hinds DA, Kayser M, Spector TD.Nat Genet. 2019 Jul;51(7):1190. doi: 10.1038/s41588-019-0446-3.PMID: 31150021IF 25.455

Seeing the impact of the Glaucoma Inheritance Study in Tasmania after 25 years.

Mackey DA, Craig JE, Hewitt AW.Clin Exp Ophthalmol. 2019 Jul;47(5):677-679. doi: 10.1111/ceo.13446. Epub 2018 Dec 18.PMID: 30467939IF 2.250

Mobile touch screen device use and associations with musculoskeletal symptoms and visual health in a nationally representative sample of Singaporean adolescents.

Toh SH, Coenen P, Howie EK, Mukherjee S, Mackey DA, Straker LM.Ergonomics. 2019 Jun;62(6):778-793. doi: 10.1080/00140139.2018.1562107. Epub 2019 Apr 23.PMID: 30575442IF 2.181

The Relationship Between Optic Disc Parameters and Female Reproductive Factors in Young Women.

Lee SSY, Yazar S, Pasquale LR, Sanfilippo PG, Hewitt AW, Hickey M, Skinner R, Mackey DA.Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):224-228. doi: 10.22608/APO.2018329. Epub 2018 Dec 31.PMID: 30596227IF 2.25

Repurposing blue laser autofluorescence to measure ocular sun exposure.

Lingham G, Burton A, Brown HA, Huynh E, Yazar S, Coroneo MT, Mackey DA.Clin Exp Ophthalmol. 2019 May;47(4):445-452. doi: 10.1111/ceo.13423. Epub 2018 Nov 14.PMID: 30345715IF 2.250

Genetic correlations between diabetes and glaucoma: an analysis of continuous and dichotomous phenotypes.

Laville V, Kang JH, Cousins CC, Iglesias AI, Nagy R, Cooke Bailey JN, Igo RP Jr, Song YE, Chasman DI, Christen WG, Kraft P, Rosner BA, Hu F, Wilson JF, Gharahkhani P, Hewitt AW, Mackey DA, Hysi PG, Hammond CJ, vanDuijn CM, Haines JL, Vitart V, Fingert JH, Hauser MA, Aschard H, Wiggs JL, Khawaja AP, MacGregor S, Pasquale LR; UK Biobank, International Glaucoma Genetics Consortium, NEIGHBORHOOD Consortium.Am J Ophthalmol. 2019 May 20. pii: S0002-9394(19)30245-4. doi: 10.1016/j.ajo.2019.05.015. [Epub ahead of print]PMID: 31121135IF 4.483

Differential stability of variant OPN1LW gene transcripts in myopic patients.

Mountford JK, Davies WIL, Griffiths LR, Yazar S, Mackey DA, Hunt DM.

Mol Vis. 2019 Mar 17;25:183-193. eCollection 2019.PMID: 30996587IF 2.174

Eye Injuries across history and the evolution of eye protection.

Hoskin AK, Mackey DA, Keay L, Agrawal R, Watson S.Acta Ophthalmol. 2019 Mar 25. doi: 10.1111/aos.14086. [Epub ahead of print]PMID: 30907494IF 3.152

IMI – Myopia Genetics Report.

Tedja MS, Haarman AEG, Meester-Smoor MA, Kaprio J, Mackey DA, Guggenheim JA, Hammond CJ, Verhoeven VJM, Klaver CCW; CREAM Consortium.Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M89-M105. doi: 10.1167/iovs. 18-25965.PMID: 30817828IF 3.812

Low 25-Hydroxyvitamin D Concentration Is Not Associated With Refractive Error in Middle-Aged and Older Western Australian Adults.

Lingham G, Yazar S, Lucas RM, Walsh JP, Zhu K, Hunter M, Lim EM, Cooke BR, Mackey DA.Transl Vis Sci Technol. 2019 Jan 22;8(1):13. doi: 10.1167/tvst.8.1.13. eCollection 2019 Jan.PMID: 30697464IF 2.399

Prevalence of FOXC1 Variants in Individuals With a Suspected Diagnosis of Primary Congenital Glaucoma.

Siggs OM, Souzeau E, Pasutto F, Dubowsky A, Smith JEH, Taranath D, Pater J, Rait JL, Narita A, Mauri L, Del Longo A, Reis A, Chappell A, Kearns LS, Staffieri SE, Elder JE, Ruddle JB, Hewitt AW, Burdon KP, Mackey DA, Craig JE.JAMA Ophthalmol. 2019 Jan 17. doi: 10.1001/jamaophthalmol.2018.5646. [Epub ahead of print] PMID: 30653210IF 6.167

Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW; Melanoma GWAS Consortium, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT,

Automatic choroidal segmentation in OCT images using supervised deep learning methods.Kugelman J, Alonso-Caneiro D, Read SA, Hamwood J, Vincent SJ, Chen FK, Collins MJ.Sci Rep. 2019 Sep 16;9(1):13298. doi: 10.1038/s41598-019-49816-4.PMID: 31527630

Generation of three induced pluripotent stem cell lines from an isolated inherited retinal dystrophy patient with RCBTB1 frameshifting mutations.

Huang Z, Zhang D, Chen SC, Thompson JA, McLaren T, Lamey T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Oct;40:101549. doi: 10.1016/j.scr.2019.101549. Epub 2019 Aug 23.PMID: 31494449IF 3.929

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.

Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD; Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group.Ophthalmology. 2019 Jun;126(6):829-838. doi: 10.1016/j.ophtha.2018.09.015. Epub 2018 Sep 20. PMID: 30244144IF 7.732

A computational framework to investigate retinal haemodynamics and tissue stress.

Rebhan J, Parker LP, Kelsey LJ, Chen FK, Doyle BJ.Biomech Model Mechanobiol. 2019 May 28. doi: 10.1007/s10237-019-01172-y. [Epub ahead of print]PMID: 31140054IF 2.829

Generation of an induced pluripotent stem cell line from a patient with retinitis pigmentosa caused by RP1 mutation.

Zhang X, Moon SY, Zhang D, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Apr 25;37:101452. doi: 10.1016/j.scr.2019.101452. [Epub ahead of print]PMID: 31059986IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with compound heterozygous mutations in the USH2A gene.

McLenachan S, Wong EYM, Zhang X, Leith F, Moon SY, Zhang D, Chen SC, Thompson

JA, McLaren T, Lamey T, De Roach JN, Atlas MD, Dilley RJ, Chen FK.Stem Cell Res. 2019 Apr;36:101420. doi: 10.1016/j.scr.2019.101420. Epub 2019 Mar 16.PMID: 30904819 IF 3.929

ENDOGENOUS ENDOPHTHALMITIS IN WESTERN AUSTRALIA: A Sixteen-Year Retrospective Study.

Gounder PA, Hille DM, Khoo YJ, Phagura RS, Chen FK.Retina. 2019 Mar 12. doi: 10.1097/IAE.0000000000002512. [Epub ahead of print]PMID: 30893275IF 3.08

Near-infrared spectroscopy parameters in patients undergoing continuous venovenous hemodiafiltration.

Chaves RCF, Tafner PFDA, Chen FK, Meneghini LB, Corrêa TD, Rabello Filho R, Cendoroglo Neto M, Santos OFPD, Serpa Neto A.Einstein (Sao Paulo). 2019 Feb 14;17(1):eAO4439. doi: 10.31744/einstein_journal/2019AO4439. English, Portuguese.PMID: 30785493 IF 0.11

Generation of the induced pluripotent stem cell line from a patient with autosomal recessive ABCA4-mediated Stargardt Macular Dystrophy.

Claassen JN, Zhang D, Chen SC, Moon SY, Lamey T, Thompson JA, McLaren T, De Roach JN, McLenachan S, Chen FK.Stem Cell Res. 2019 Jan;34:101352. doi: 10.1016/j.scr.2018.11.013. Epub 2018 Nov 30.PMID: 30634128IF 3.929

Generation of two induced pluripotent stem cell lines from a patient with dominant PRPF31 mutation and a related non-penetrant carrier.

McLenachan S, Zhang D, Zhang X, Chen SC, Lamey T, Thompson JA, McLaren T, De Roach JN, Fletcher S, Chen FK.Stem Cell Res. 2019 Jan;34:101357. doi: 10. 1016/j.scr.2018.11.018. Epub 2018 Dec 10.PMID:30611018IF 3.929

Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).

Chen FK, Zhang X, Eintracht J, Zhang D, Arunachalam S, Thompson JA, Chelva E, Mallon D, Chen SC, McLaren T, Lamey T, De Roach J, McLenachan S.Doc Ophthalmol. 2019 Feb;138(1):55-70. doi: 10.1007/s10633-018-9665-7. Epub 2018 Nov 16. PMID: 30446867IF 1.460

BRANCH RETINAL VEIN OCCLUSION SECONDARY TO A RETINAL ARTERIOLAR MACROANEURYSM: A NOVEL MECHANISM SUPPORTED BY MULTIMODAL IMAGING.

Chen Y, Chen SDM, Chen FK.Retin Cases Brief Rep. 2019 Winter;13(1):10-14. doi: 10.1097/ICB.0000000000000517. PMID: 28079651IF 0.79

Physiology and Pharmacology

XEN Gel Stent to Treat ICE Syndrome: 4 Cases.

Lin MM, Morgan WH, Kolomeyer NN, Moster SJ, Zheng CX, Giubilato A, Moster MR.J Glaucoma. 2019 Dec;28(12):1090-1094. doi: 10.1097/IJG.0000000000001341.PMID: 31425336IF 1.661

Topographic Distribution of Contractile Protein in the Human Macular Microvasculature.

Yu PK, An D, Balaratnasingam C, Cringle SJ, Yu DY.Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4574-4582. doi: 10.1167/iovs. 19-26986.PMID: 31675074IF 3.812

The Nature and Frequency of Outer Retinal Disruption in Idiopathic Multifocal Choroiditis Associated With Persistent Fundus Hyperautofluorescence.

Kaden TR, Gattoussi S, Dolz-Marco R, Balaratnasingam C, Yannuzzi LA, Freund KB.Ophthalmic Surg Lasers Imaging Retina. 2019 Nov 1;50(11):675-683. doi: 10.3928/23258160-20191031-02.PMID: 31755966IF 1.422

Correlation between Histologic and OCT Angiography Analysis of Macular Circulation.

Balaratnasingam C, An D, Freund KB, Francke A, Yu DY.Ophthalmology. 2019 May 23. pii: S0161-6420(19)30795-X. doi: 10.1016/j.ophtha.2019.05.022. [Epub ahead of print] No abstract available.PMID: 31227322IF 7.732

Use of trypan blue as an aqueous tracer dye to investigate hypotony where cyclodialysis cleft is suspected.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 15. doi: 10.1111/ceo.13558. [Epub ahead of print]PMID: 31090997IF 2.250

Bataille V, Falchi M, Han J, Martin NG.Nat Commun. 2019 Jan 14;10(1):299. doi: 10.1038/s41467-018-08078-w. PMID: 30643134IF 11.878

Author Correction: Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Iglesias AI, Mishra A, Vitart V, Bykhovskaya Y, Höhn R, Springelkamp H, Cuellar-Partida G, Gharahkhani P, Bailey JNC, Willoughby CE, Li X, Yazar S, Nag A, Khawaja AP, Polašek O, Siscovick D, Mitchell P, Tham YC, Haines JL, Kearns LS, Hayward C, Shi Y, van Leeuwen EM, Taylor KD; Blue Mountains Eye Study – GWAS group, Bonnemaijer P, Rotter JI, Martin NG, Zeller T, Mills RA, Souzeau E, Staffieri SE, Jonas JB, Schmidtmann I, Boutin T, Kang JH, Lucas SEM, Wong TY, Beutel ME, Wilson JF; Wellcome Trust Case Control Consortium 2 (WTCCC2); NEIGHBORHOOD consortium, Uitterlinden AG, Vithana EN, Foster PJ, Hysi PG, Hewitt AW, Khor CC, Pasquale LR, Montgomery GW, Klaver CCW, Aung T, Pfeiffer N, Mackey DA, Hammond CJ, Cheng CY, Craig JE, Rabinowitz YS, Wiggs JL, Burdon KP, van Duijn CM, MacGregor S.Nat Commun. 2019 Jan 8;10(1):155. doi: 10.1038/s41467-018-07819-1. PMID: 30622277IF 11.878

Vitamin D and its pathway genes in myopia: systematic review and meta-analysis.

Tang SM, Lau T, Rong SS, Yazar S, Chen LJ, Mackey DA, Lucas RM, Pang CP, Yam JC.Br J Ophthalmol. 2019 Jan;103(1):8-17. doi: 10.1136/bjophthalmol-2018-312159. Epub 2018 Jul 17. PMID: 30018147IF 3.615

Current state and future prospects of artificial intelligence in ophthalmology: a review.

Hogarty DT, Mackey DA, Hewitt AW.Clin Exp Ophthalmol. 2019 Jan;47(1): 128-139. doi: 10.1111/ceo.13381. Epub 2018 Sep 30.PMID: 30155978IF 2.250

Traumatic hyphaema in children: a retrospective and prospective study of outcomes at an Australian paediatric centre.

Richards MD, Barnes K, Yardley AE, Hanman K, Lam GC, Mackey DA.BMJ Open Ophthalmol. 2019 Jan 30;4(1):e000215. doi: 10.1136/bmjophth-2018-000215. eCollection 2019.PMID: 31179388

Ocular Tissue Engineering Lab

Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in Age-Related Macular Degeneration.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Tindill N, Aung KZ, McGuinness MB, Makeyeva G, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Guymer RH.Ophthalmol Retina. 2019 Dec 16. pii: S2468-6530(19)30675-X. doi: 10.1016/j.oret.2019.12.011. [Epub ahead of print]PMID: 32088159IF 6.1

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK.Lung Cancer. 2020 Feb;140:87-92. doi: 10.1016/j.lungcan.2019.12.018. Epub 2019 Dec 31.PMID: 31901768IF 4.599

Analysis of the ABCA4 c.[2588G>C; 5603A>T] Allele in the Australian Population.

Thompson JA, Chiang JP, De Roach JN, McLaren TL, Chen FK, Hoffmann L, Campbell I, Lamey TM.Adv Exp Med Biol. 2019;1185:269-273. doi: 10.1007/978-3-030-27378-1_44.PMID: 31884623IF 2.126

Assessing the Use of Incorrectly Scaled Optical Coherence Tomography Angiography Images in Peer-Reviewed Studies: A Systematic Review.

Llanas S, Linderman RE, Chen FK, Carroll J.JAMA Ophthalmol. 2019 Nov 27. doi: 10.1001/jamaophthalmol.2019.4821. [Epub ahead of print]PMID: 31774456 IF 6.167

Reply.

Guymer RH, Wu Z, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Luu CD; LEAD Study Group.Ophthalmology. 2019 Dec;126(12):e92-e93. doi: 10.1016/j.ophtha.2019.07.017. No abstract available.PMID: 31759505IF 7.732

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision.

Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, Warrier SK, Stark AL, Rolfe OJ, Palmer JM, Hayward NK.Transl Vis Sci Technol. 2019 Nov 14;8(6):12. doi: 10.1167/tvst.8.6.12. eCollection 2019 Nov.PMID: 31737436IF 2.399

Automatic Detection of Cone Photoreceptors With Fully Convolutional Networks.

Hamwood J, Alonso-Caneiro D, Sampson DM, Collins MJ, Chen FK.Transl Vis Sci Technol. 2019 Nov 12;8(6):10. doi: 10.1167/tvst.8.6.10. eCollection 2019 Nov.PMID: 31737434IF 2.399

Clinical validation of the RTVue optical coherence tomography angiography image quality indicators.

Ali N, Sampson DM, Au Yong A, Jeewa R, Rajgopal S, Dutt DDCS, Mohamed S, Mohamed S, Menghini M, Hansen A, Chen FK.Clin Exp Ophthalmol. 2019 Nov 9. doi: 10.1111/ceo.13680. [Epub ahead of print]PMID: 31705836IF 2.250

Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration.

McGuinness MB, Finger RP, Wu Z, Luu CD, Chen FK, Arnold JJ, Chakravarthy U, Heriot WJ, Runciman J, Guymer RH; LEAD Study Group.Transl Vis Sci Technol. 2019 Sep 11;8(5):3. doi: 10.1167/tvst.8.5.3. eCollection 2019 Sep.PMID: 31588369IF 2.399

Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report.

Wu Z, Luu CD, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, Harper CA, Wickremasinghe SS, Sandhu SS, McGuinness MB, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Wintergerst MWM, Gorgi Zadeh S, Schultz T, Finger RP, Cohn AC, Baglin EK, Sharangan P, Guymer RH; LEAD Study Group.Ophthalmol Retina. 2019 Dec;3(12):1026-1034. doi: 10.1016/j.oret.2019.07.008. Epub 2019 Jul 22.PMID: 31582304 IF 6.1

Optimization of silk fibroin membranes for retinal implantation.

Suzuki S, Shadforth AMA, McLenachan S, Zhang D, Chen SC, Walshe J, Lidgerwood GE, Pébay A, Chirila TV, Chen FK, Harkin DG.Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110131. doi: 10.1016/j.msec.2019.110131. Epub 2019 Aug 29. PMID: 31546376 IF 4.959

165

PUBLICATIONS 2019

Genetics and Epidemiology

Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol.

McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, Mackey DA, Butler JS, Loughman J.HRB Open Res. 2019 Jul 23;2:15. doi: 10.12688/hrbopenres.12914.1. eCollection 2019.PMID: 32002514

Association of Genetic Variation with Keratoconus.

McComish BJ, Sahebjada S, Bykhovskaya Y, Willoughby CE, Richardson AJ, Tenen A, Charlesworth JC, MacGregor S, Mitchell P, Lucas SEM, Mills RA, Mackey DA, Li X, Wang JJ, Jensen RA, Rotter JI, Taylor KD, Hewitt AW, Rabinowitz YS, Baird PN, Craig JE, Burdon KP.JAMA Ophthalmol. 2019 Dec 19. doi: 10.1001/jamaophthalmol.2019.5293. [Epub ahead of print]PMID: 31855235IF 6.167

Estimation of heritability and familial correlation in myopia is not affected by past sun exposure.

Charng J, Sanfilippo PG, Lingham G, Stevenson LJ, Mackey DA, Yazar S.Ophthalmic Genet. 2019 Dec;40(6): 500-506. doi: 10.1080/13816810.2019. 1696376. Epub 2019 Dec 6.PMID: 31810409IF 1.285

Genome-wide association analysis of 95 549 individuals identifies novel loci and genes influencing optic disc morphology.

Han X, Qassim A, An J, Marshall H, Zhou T, Ong JS, Hassall MM, Hysi PG, Foster PJ, Khaw PT, Mackey DA, Gharahkhani P, Khawaja AP, Hewitt AW, Craig JE, MacGregor S.Hum Mol Genet. 2019 Nov 1;28(21): 3680-3690. doi: 10.1093/hmg/ddz193.PMID: 31809533IF 4.544

Multi-trait genome-wide association study identifies new loci associated with optic disc parameters.

Bonnemaijer PWM, Leeuwen EMV, Iglesias AI, Gharahkhani P, Vitart V, Khawaja AP, Simcoe M, Höhn R, Cree AJ, Igo RP; International Glaucoma

Genetics Consortium; NEIGHBORHOOD consortium; UK Biobank Eye and Vision Consortium, Gerhold-Ay A, Nickels S, Wilson JF, Hayward C, Boutin TS, Polašek O, Aung T, Khor CC, Amin N, Lotery AJ, Wiggs JL, Cheng CY, Hysi PG, Hammond CJ, Thiadens AAHJ, MacGregor S, Klaver CCW, Duijn CMV.Commun Biol. 2019 Nov 27;2:435. doi: 10.1038/s42003-019-0634-9. eCollection 2019.PMID: 31798171 IF under calculation

How does spending time outdoors protect against myopia? A review.

Lingham G, Mackey DA, Lucas R, Yazar S.Br J Ophthalmol. 2019 Nov 13. pii: bjophthalmol-2019-314675. doi: 10.1136/bjophthalmol-2019-314675. [Epub ahead of print] Review.PMID: 31722876IF 3.615

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol.

Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, Doherty P, Adams C, Gardner E, Hogg R, McFarland M, Preston J, Verghis R, Loughman JJ, Flitcroft I, Mackey DA, Lee SS, Hammond C, Congdon N, Clarke M.Br J Ophthalmol. 2019 Oct 25. pii: bjophthalmol-2019-314819. doi: 10.1136/bjophthalmol-2019-314819. [Epub ahead of print]PMID: 31653669IF 3.615

Epha2 genotype influences ultraviolet radiation induced cataract in mice.

Dave A, Craig JE, Skrzypiec K, Quinn S, Barnes M, Di Girolamo N, Mackey DA, Burdon KP, de Iongh RU, Sharma S.Exp Eye Res. 2019 Nov;188:107806. doi: 10.1016/j.exer.2019.107806. Epub 2019 Sep 17.PMID: 31539542IF 2.998

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.

BIRTH-GENE (BIG) Study Working Group, Huang T, Wang T, Zheng Y, Ellervik C, Li X, Gao M, Fang Z, Chai JF, Ahluwalia TVS, Wang Y, Voortman T, Noordam

R, Frazier-Wood A, Scholz M, Sonestedt E, Akiyama M, Dorajoo R, Zhou A, Kilpeläinen TO, Kleber ME, Crozier SR, Godfrey KM, Lemaitre R, Felix JF, Shi Y, Gupta P, Khor CC, Lehtimäki T, Wang CA, Tiesler CMT, Thiering E, Standl M, Rzehak P, Marouli E, He M, Lecoeur C, Corella D, Lai CQ, Moreno LA, Pitkänen N, Boreham CA, Zhang T, Saw SM, Ridker PM, Graff M, van Rooij FJA, Uitterlinden AG, Hofman A, van Heemst D, Rosendaal FR, de Mutsert R, Burkhardt R, Schulz CA, Ericson U, Kamatani Y, Yuan JM, Power C, Hansen T, Sørensen TIA, Tjønneland A, Overvad K, Delgado G, Cooper C, Djousse L, Rivadeneira F, Jameson K, Zhao W, Liu J, Lee NR, Raitakari O, Kähönen M, Viikari J, Grote V, Langhendries JP, Koletzko B, Escribano J, Verduci E, Dedoussis G, Yu C, Tham YC, Lim B, Lim SH, Froguel P, Balkau B, Fink NR, Vinding RK, Sevelsted A, Bisgaard H, Coltell O, Dallongeville J, Gottrand F, Pahkala K, Niinikoski H, Hyppönen E, Pedersen O, März W, Inskip H, Jaddoe VWV, Dennison E, Wong TY, Sabanayagam C, Tai ES, Mohlke KL, Mackey DA, Gruszfeld D, Deloukas P, Tucker KL, Fumeron F, Bønnelykke K, Rossing P, Estruch R, Ordovas JM, Arnett DK, Meirhaeghe A, Amouyel P, Cheng CY, Sim X, Teo YY, van Dam RM, Koh WP, Orho-Melander M, Loeffler M, Kubo M, Thiery J, Mook-Kanamori DO, Mozaffarian D, Psaty BM, Franco OH, Wu T, North KE, Davey Smith G, Chavarro JE, Chasman DI, Qi L.JAMA Netw Open. 2019 Sep 4;2(9):e1910915. doi: 10.1001/jamanetworkopen.2019.10915.PMID: 31539074

The challenge of an adequate outcome in trials for genetic eye disease such as Leber hereditary optic neuropathy.

Mackey DA, Kearns LS.Clin Exp Ophthalmol. 2019 Aug;47(6):704-705. doi: 10.1111/ceo.13586. No abstract available.PMID: 31397049IF 2.250

Eye injury registries – A systematic review.

Hoskin AK, Watson SL, Mackey DA, Agrawal R, Keay L.Injury. 2019 Nov;50(11):1839-1846. doi: 10.1016/j.injury.2019.07.019. Epub 2019 Jul 26. Review.PMID: 31378543IF 1.834

Use of trypan blue to assess lymphatic function following trabeculectomy.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 10. doi: 10.1111/ceo.13534. [Epub ahead of print]PMID: 31074572IF 2.250

Retinal capillary perfusion: Spatial and temporal heterogeneity.

Yu DY, Cringle SJ, Yu PK, Balaratnasingam C, Mehnert A, Sarunic MV, An D, Su EN.Prog Retin Eye Res. 2019 May;70:23-54. doi: 10.1016/j.preteyeres.2019.01.001. Epub 2019 Feb 13. Review.PMID: 30769149IF 11.768

Association between focal lamina cribrosa defects and optic disc haemorrhage in glaucoma.

Mistry V, An D, Barry CJ, House PH, Morgan WH.Br J Ophthalmol. 2019 Apr 25. pii: bjophthalmol-2018-313775. doi: 10.1136/bjophthalmol-2018-313775. [Epub ahead of print]PMID: 31023711IF 3.615

Association of Exercise and Swimming Goggles With Modulation of Cerebro-ocular Hemodynamics and Pressures in a Model of Spaceflight-Associated Neuro-ocular Syndrome.

Scott JM, Tucker WJ, Martin D, Crowell JB, Goetchius E, Ozgur O, Hamilton S, Otto C, Gonzales R, Ritter M, Newby N, DeWitt J, Stenger MB, Ploutz-Snyder R, Ploutz-Snyder L, Morgan WH, Haykowsky MJ.JAMA Ophthalmol. 2019 Apr 18. doi: 10.1001/jamaophthalmol.2019.0459. [Epub ahead of print]PMID: 30998818IF 6.167

Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.

Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA.Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17.PMID: 30659849IF 7.732

Comparison of Ophthalmic Medication Prices Between the United States and Australia.

Parikh R, Feng PW, Tainsh L, Sakurada Y, Balaratnasingam C, Khurana RN, Hemmati H, Modi YS.JAMA Ophthalmol. 2019 Jan 10. doi: 10.1001/jamaophthalmol.2018.6395. [Epub ahead of print] Erratum in:

JAMA Ophthalmol. 2019 May 9PMID: 30629105IF 6.167

Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis (IRVAN) in a Patient Without IRVAN History.

Balaratnasingam C, Yannuzzi LA, Franchina M, Freund KB.JAMA Ophthalmol. 2019 Feb 1;137(2): 230-232. doi: 10.1001/jamaophthalmol. 2018.5247. No abstract available.PMID: 30419083IF 6.167

Experimental Immunology

MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and is Influenced by the Microbiota.

Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, Hülsdünker J, Varelias A, Vetizou M, Kuns RD, Robb RJ, Zhang P, Blazar BR, Thomas R, Begun J, Waddell N, Trinchieri G, Zeiser R, Clouston AD, Degli-Esposti MA, Hill GR.Immunity. 2019 Nov 19;51(5):885-898.e7. doi: 10.1016/j.immuni.2019.08.011. Epub 2019 Sep 18.PMID: 31542340IF 21.522

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.

Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, Cursons J, Hennessy R, Hutchinson DS, Harrison C, Kita B, Vivier E, Webb AI, Degli-Esposti MA, Davis MJ, Huntington ND, Souza-Fonseca-Guimaraes F.Sci Signal. 2019 Aug 27;12(596). pii: eaat7527. doi: 10.1126/scisignal.aat7527.PMID: 31455725IF 6.565

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ.Sci Transl Med. 2019 Jul 17;11(501). pii: eaav7816. doi: 10.1126/scitranslmed.aav7816.PMID: 31316010IF 17.2

The Avidity Game: Selecting Natural-Born Killers.

Andoniou CE, Schuster IS, Degli-Esposti MA.Immunity. 2019 Jun 18;50(6):1337-1339. doi: 10.1016/j.immuni.2019.05.018.PMID: 31216454IF 21.522

Three-year follow-up of Phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age related macular degeneration.

Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ.Am J Ophthalmol. 2019 Mar 13. pii: S0002-9394(19)30104-7. doi: 10.1016/j.ajo.2019.03.006. [Epub ahead of print]PMID: 30878487IF 4.483

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation.

Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, Daly S, Varelias A, Tey SK, Degli-Esposti MA, Hill GR.Science. 2019 Jan 18;363(6424):288-293. doi: 10.1126/science.aat0066.PMID: 30655443IF 41.063

Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity.

Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, Yu T, McGinley AM, Quinn SM, Massilamany C, Reddy J, Forrester JV, Mills KH.EMBO Rep. 2019 May;20(5). pii: e47121. doi: 10.15252/embr.201847121. Epub 2019 Mar 20.PMID: 30894405IF 8.383

Transmission Electron Microscopy Data on drusen-like deposits in the retinal degeneration sTg-IRBP: HEL mouse model.

Liu YH, Mölzer C, Milne GC, Kuffová L, Forrester JV.Data Brief. 2018 Dec 6;22:140-144. doi: 10.1016/j.dib.2018.12.007. eCollection 2019 Feb.PMID: 30581918IF 0.970

Retinal Genomics and Therapy

Postmitotic Cone Migration Mechanisms in the Mammalian Retina.

Carvalho LS, Mellough CB.Adv Exp Med Biol. 2019;1185:489-493. doi: 10.1007/978-3-030-27378-1_80. Review.PMID: 31884659IF 2.126

The Role of the Voltage-Gated Potassium Channel Proteins Kv8.2 and Kv2.1 in Vision and Retinal Disease: Insights from the Study of Mouse Gene Knock-Out Mutations.

Hart NS, Mountford JK, Voigt V, Fuller-Carter P, Barth M, Nerbonne JM, Hunt DM, Carvalho LS.eNeuro. 2019 Feb 25;6(1). pii: ENEURO.0032-19.2019. doi: 10.1523/ENEURO.0032-19.2019. eCollection

2019 Jan-Feb.PMID: 30820446IF 3.46

Phototactic tails: Evolution and molecular basis of a novel sensory trait in sea snakes.Crowe-Riddell JM, Simões BF, Partridge JC, Hunt DM, Delean S, Schwerdt JG, Breen J, Ludington A, Gower DJ, Sanders KL.Mol Ecol. 2019 Apr;28(8):2013-2028. doi: 10.1111/mec.15022. Epub 2019 Feb 15.PMID: 30767303IF 5.855

Systematic Comparison of Retinal Organoid Differentiation from Human Pluripotent Stem Cells Reveals Stage Specific, Cell Line, and Methodological Differences.Mellough CB, Collin J, Queen R, Hilgen G, Dorgau B, Zerti D, Felemban M, White K, Sernagor E, Lako M.Stem Cells Transl Med. 2019 Jul;8(7): 694-706. doi: 10.1002/sctm.18-0267. Epub 2019 Mar 27.PMID: 30916455IF 5.962

An integrated transcriptional analysis of the developing human retina.Mellough CB, Bauer R, Collin J, Dorgau B, Zerti D, Dolan DWP, Jones CM, Izuogu OG, Yu M, Hallam D, Steyn JS, White K, Steel DH, Santibanez-Koref M, Elliott DJ, Jackson MS, Lindsay S, Grellscheid S, Lako M.Development. 2019 Jan 29;146(2). pii: dev169474. doi: 10.1242/dev.169474.PMID: 30696714IF 5.763

Lions Outback Vision

On-call telehealth for visiting optometry in regional Western Australia improves patient access to eye care.Nguyen AA, Baker A, Turner AW.Clin Exp Optom. 2019 Oct 23. doi: 10.1111/cxo.12979. [Epub ahead of print] No abstract available.PMID: 31646665IF 1.559

Evaluating the impact of the Lions Outback Vision mobile ophthalmology service.Fu S, Jeyaraj J, Turner AW.Clin Exp Ophthalmol. 2019 Apr 25. doi: 10.1111/ceo.13522. [Epub ahead of print] No abstract available.PMID: 31021477IF 2.250

Review of cataract surgery in rural north Western Australia with the Lions Outback Vision.McGlacken-Byrne A, Turner AW, Drinkwater J.Clin Exp Ophthalmol. 2019 Feb 22. doi: 10.1111/ceo.13481. [Epub ahead of print] No abstract available. PMID: 30801933IF 2.250

Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Drinkwater JJ, Davis TME, Turner AW, Bruce DG, Davis WA.Diabetes Care. 2019 Feb;42(2):288-296. doi: 10.2337/dc18-1556. Epub 2018 Dec 6.PMID: 30523034IF 15.270

Clinicians

Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial.

Mehta H, Lim LL, Nguyen V, Qatarneh D, Wickremasinghe SS, Hodgson LAB, Quin GJ, McAllister IL, Gillies MC, Fraser-Bell S.Ophthalmol Retina. 2019 Mar;3(3):286-287. doi: 10.1016/j.oret.2018.10.010. Epub 2018 Oct 25. No abstract available.PMID: 31014709IF 6.1

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL.JAMA Ophthalmol. 2019 Jan 24. doi: 10.1001/jamaophthalmol.2018.6776. [Epub ahead of print]PMID: 30676617 IF 6.167

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators.Ophthalmology. 2019 May;126(5):723-734. doi: 10.1016/j.ophtha.2018.11.025. Epub 2018 Nov 29.PMID: 30502372IF 7.732

Using the first-eye prediction error in cataract surgery to refine the refractive outcome of the second eye.

Turnbull AMJ, Barrett GD.J Cataract Refract Surg. 2019 Jul 17. pii: S0886-3350(19)30281-0. doi: 10.1016/j.jcrs.2019.04.008. [Epub ahead of print]PMID: 31326224IF 2.238

New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.

Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS.Semin Arthritis Rheum. 2019 Jun 10. pii: S0049-0172(18)30557-2. doi: 10.1016/j.

semarthrit.2019.06.004. [Epub ahead of print] Review.PMID: 31301816IF 5.072

Current ophthalmology practice patterns for syphilitic uveitis.

Oliver GF, Stathis RM, Furtado JM, Arantes TE, McCluskey PJ, Matthews JM; International Ocular Syphilis Study Group, Smith JR.Br J Ophthalmol. 2019 Jan 30. pii: bjophthalmol-2018-313207. doi: 10.1136/bjophthalmol-2018-313207. [Epub ahead of print]PMID: 31021330IF 3.615

Reduced expression of apolipoprotein E and immunoglobulin heavy constant gamma 1 proteins in Fuchs endothelial corneal dystrophy.

Kuot A, Ronci M, Mills R, Klebe S, Snibson G, Wiffen S, Loh R, Corbett M, Zhou T, Chataway T, Burdon KP, Craig JE, Urbani A, Sharma S.Clin Exp Ophthalmol. 2019 Jun 17. doi: 10.1111/ceo.13569. [Epub ahead of print] PMID: 31206232IF 2.250

Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.

Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group.Ophthalmology. 2019 Apr;126(4):540-549. doi: 10.1016/j.ophtha.2018.09.041. Epub 2018 Oct 4.PMID: 30292541IF 3.615

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.

Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group.Acta Ophthalmol. 2019 Nov;97(7): e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9.PMID: 30968592IF 3.152

165

PUBLICATIONS 2019

Genetics and Epidemiology

Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol.

McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, Mackey DA, Butler JS, Loughman J.HRB Open Res. 2019 Jul 23;2:15. doi: 10.12688/hrbopenres.12914.1. eCollection 2019.PMID: 32002514

Association of Genetic Variation with Keratoconus.

McComish BJ, Sahebjada S, Bykhovskaya Y, Willoughby CE, Richardson AJ, Tenen A, Charlesworth JC, MacGregor S, Mitchell P, Lucas SEM, Mills RA, Mackey DA, Li X, Wang JJ, Jensen RA, Rotter JI, Taylor KD, Hewitt AW, Rabinowitz YS, Baird PN, Craig JE, Burdon KP.JAMA Ophthalmol. 2019 Dec 19. doi: 10.1001/jamaophthalmol.2019.5293. [Epub ahead of print]PMID: 31855235IF 6.167

Estimation of heritability and familial correlation in myopia is not affected by past sun exposure.

Charng J, Sanfilippo PG, Lingham G, Stevenson LJ, Mackey DA, Yazar S.Ophthalmic Genet. 2019 Dec;40(6): 500-506. doi: 10.1080/13816810.2019. 1696376. Epub 2019 Dec 6.PMID: 31810409IF 1.285

Genome-wide association analysis of 95 549 individuals identifies novel loci and genes influencing optic disc morphology.

Han X, Qassim A, An J, Marshall H, Zhou T, Ong JS, Hassall MM, Hysi PG, Foster PJ, Khaw PT, Mackey DA, Gharahkhani P, Khawaja AP, Hewitt AW, Craig JE, MacGregor S.Hum Mol Genet. 2019 Nov 1;28(21): 3680-3690. doi: 10.1093/hmg/ddz193.PMID: 31809533IF 4.544

Multi-trait genome-wide association study identifies new loci associated with optic disc parameters.

Bonnemaijer PWM, Leeuwen EMV, Iglesias AI, Gharahkhani P, Vitart V, Khawaja AP, Simcoe M, Höhn R, Cree AJ, Igo RP; International Glaucoma

Genetics Consortium; NEIGHBORHOOD consortium; UK Biobank Eye and Vision Consortium, Gerhold-Ay A, Nickels S, Wilson JF, Hayward C, Boutin TS, Polašek O, Aung T, Khor CC, Amin N, Lotery AJ, Wiggs JL, Cheng CY, Hysi PG, Hammond CJ, Thiadens AAHJ, MacGregor S, Klaver CCW, Duijn CMV.Commun Biol. 2019 Nov 27;2:435. doi: 10.1038/s42003-019-0634-9. eCollection 2019.PMID: 31798171 IF under calculation

How does spending time outdoors protect against myopia? A review.

Lingham G, Mackey DA, Lucas R, Yazar S.Br J Ophthalmol. 2019 Nov 13. pii: bjophthalmol-2019-314675. doi: 10.1136/bjophthalmol-2019-314675. [Epub ahead of print] Review.PMID: 31722876IF 3.615

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol.

Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, Doherty P, Adams C, Gardner E, Hogg R, McFarland M, Preston J, Verghis R, Loughman JJ, Flitcroft I, Mackey DA, Lee SS, Hammond C, Congdon N, Clarke M.Br J Ophthalmol. 2019 Oct 25. pii: bjophthalmol-2019-314819. doi: 10.1136/bjophthalmol-2019-314819. [Epub ahead of print]PMID: 31653669IF 3.615

Epha2 genotype influences ultraviolet radiation induced cataract in mice.

Dave A, Craig JE, Skrzypiec K, Quinn S, Barnes M, Di Girolamo N, Mackey DA, Burdon KP, de Iongh RU, Sharma S.Exp Eye Res. 2019 Nov;188:107806. doi: 10.1016/j.exer.2019.107806. Epub 2019 Sep 17.PMID: 31539542IF 2.998

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.

BIRTH-GENE (BIG) Study Working Group, Huang T, Wang T, Zheng Y, Ellervik C, Li X, Gao M, Fang Z, Chai JF, Ahluwalia TVS, Wang Y, Voortman T, Noordam

R, Frazier-Wood A, Scholz M, Sonestedt E, Akiyama M, Dorajoo R, Zhou A, Kilpeläinen TO, Kleber ME, Crozier SR, Godfrey KM, Lemaitre R, Felix JF, Shi Y, Gupta P, Khor CC, Lehtimäki T, Wang CA, Tiesler CMT, Thiering E, Standl M, Rzehak P, Marouli E, He M, Lecoeur C, Corella D, Lai CQ, Moreno LA, Pitkänen N, Boreham CA, Zhang T, Saw SM, Ridker PM, Graff M, van Rooij FJA, Uitterlinden AG, Hofman A, van Heemst D, Rosendaal FR, de Mutsert R, Burkhardt R, Schulz CA, Ericson U, Kamatani Y, Yuan JM, Power C, Hansen T, Sørensen TIA, Tjønneland A, Overvad K, Delgado G, Cooper C, Djousse L, Rivadeneira F, Jameson K, Zhao W, Liu J, Lee NR, Raitakari O, Kähönen M, Viikari J, Grote V, Langhendries JP, Koletzko B, Escribano J, Verduci E, Dedoussis G, Yu C, Tham YC, Lim B, Lim SH, Froguel P, Balkau B, Fink NR, Vinding RK, Sevelsted A, Bisgaard H, Coltell O, Dallongeville J, Gottrand F, Pahkala K, Niinikoski H, Hyppönen E, Pedersen O, März W, Inskip H, Jaddoe VWV, Dennison E, Wong TY, Sabanayagam C, Tai ES, Mohlke KL, Mackey DA, Gruszfeld D, Deloukas P, Tucker KL, Fumeron F, Bønnelykke K, Rossing P, Estruch R, Ordovas JM, Arnett DK, Meirhaeghe A, Amouyel P, Cheng CY, Sim X, Teo YY, van Dam RM, Koh WP, Orho-Melander M, Loeffler M, Kubo M, Thiery J, Mook-Kanamori DO, Mozaffarian D, Psaty BM, Franco OH, Wu T, North KE, Davey Smith G, Chavarro JE, Chasman DI, Qi L.JAMA Netw Open. 2019 Sep 4;2(9):e1910915. doi: 10.1001/jamanetworkopen.2019.10915.PMID: 31539074

The challenge of an adequate outcome in trials for genetic eye disease such as Leber hereditary optic neuropathy.

Mackey DA, Kearns LS.Clin Exp Ophthalmol. 2019 Aug;47(6):704-705. doi: 10.1111/ceo.13586. No abstract available.PMID: 31397049IF 2.250

Eye injury registries – A systematic review.

Hoskin AK, Watson SL, Mackey DA, Agrawal R, Keay L.Injury. 2019 Nov;50(11):1839-1846. doi: 10.1016/j.injury.2019.07.019. Epub 2019 Jul 26. Review.PMID: 31378543IF 1.834

Use of trypan blue to assess lymphatic function following trabeculectomy.

Khoo YJ, Abdullah AAH, Yu DY, Morgan WH.Clin Exp Ophthalmol. 2019 May 10. doi: 10.1111/ceo.13534. [Epub ahead of print]PMID: 31074572IF 2.250

Retinal capillary perfusion: Spatial and temporal heterogeneity.

Yu DY, Cringle SJ, Yu PK, Balaratnasingam C, Mehnert A, Sarunic MV, An D, Su EN.Prog Retin Eye Res. 2019 May;70:23-54. doi: 10.1016/j.preteyeres.2019.01.001. Epub 2019 Feb 13. Review.PMID: 30769149IF 11.768

Association between focal lamina cribrosa defects and optic disc haemorrhage in glaucoma.

Mistry V, An D, Barry CJ, House PH, Morgan WH.Br J Ophthalmol. 2019 Apr 25. pii: bjophthalmol-2018-313775. doi: 10.1136/bjophthalmol-2018-313775. [Epub ahead of print]PMID: 31023711IF 3.615

Association of Exercise and Swimming Goggles With Modulation of Cerebro-ocular Hemodynamics and Pressures in a Model of Spaceflight-Associated Neuro-ocular Syndrome.

Scott JM, Tucker WJ, Martin D, Crowell JB, Goetchius E, Ozgur O, Hamilton S, Otto C, Gonzales R, Ritter M, Newby N, DeWitt J, Stenger MB, Ploutz-Snyder R, Ploutz-Snyder L, Morgan WH, Haykowsky MJ.JAMA Ophthalmol. 2019 Apr 18. doi: 10.1001/jamaophthalmol.2019.0459. [Epub ahead of print]PMID: 30998818IF 6.167

Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.

Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA.Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17.PMID: 30659849IF 7.732

Comparison of Ophthalmic Medication Prices Between the United States and Australia.

Parikh R, Feng PW, Tainsh L, Sakurada Y, Balaratnasingam C, Khurana RN, Hemmati H, Modi YS.JAMA Ophthalmol. 2019 Jan 10. doi: 10.1001/jamaophthalmol.2018.6395. [Epub ahead of print] Erratum in:

JAMA Ophthalmol. 2019 May 9PMID: 30629105IF 6.167

Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis (IRVAN) in a Patient Without IRVAN History.

Balaratnasingam C, Yannuzzi LA, Franchina M, Freund KB.JAMA Ophthalmol. 2019 Feb 1;137(2): 230-232. doi: 10.1001/jamaophthalmol. 2018.5247. No abstract available.PMID: 30419083IF 6.167

Experimental Immunology

MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and is Influenced by the Microbiota.

Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, Hülsdünker J, Varelias A, Vetizou M, Kuns RD, Robb RJ, Zhang P, Blazar BR, Thomas R, Begun J, Waddell N, Trinchieri G, Zeiser R, Clouston AD, Degli-Esposti MA, Hill GR.Immunity. 2019 Nov 19;51(5):885-898.e7. doi: 10.1016/j.immuni.2019.08.011. Epub 2019 Sep 18.PMID: 31542340IF 21.522

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.

Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, Cursons J, Hennessy R, Hutchinson DS, Harrison C, Kita B, Vivier E, Webb AI, Degli-Esposti MA, Davis MJ, Huntington ND, Souza-Fonseca-Guimaraes F.Sci Signal. 2019 Aug 27;12(596). pii: eaat7527. doi: 10.1126/scisignal.aat7527.PMID: 31455725IF 6.565

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ.Sci Transl Med. 2019 Jul 17;11(501). pii: eaav7816. doi: 10.1126/scitranslmed.aav7816.PMID: 31316010IF 17.2

The Avidity Game: Selecting Natural-Born Killers.

Andoniou CE, Schuster IS, Degli-Esposti MA.Immunity. 2019 Jun 18;50(6):1337-1339. doi: 10.1016/j.immuni.2019.05.018.PMID: 31216454IF 21.522

Three-year follow-up of Phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age related macular degeneration.

Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ.Am J Ophthalmol. 2019 Mar 13. pii: S0002-9394(19)30104-7. doi: 10.1016/j.ajo.2019.03.006. [Epub ahead of print]PMID: 30878487IF 4.483

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation.

Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, Daly S, Varelias A, Tey SK, Degli-Esposti MA, Hill GR.Science. 2019 Jan 18;363(6424):288-293. doi: 10.1126/science.aat0066.PMID: 30655443IF 41.063

Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity.

Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, Yu T, McGinley AM, Quinn SM, Massilamany C, Reddy J, Forrester JV, Mills KH.EMBO Rep. 2019 May;20(5). pii: e47121. doi: 10.15252/embr.201847121. Epub 2019 Mar 20.PMID: 30894405IF 8.383

Transmission Electron Microscopy Data on drusen-like deposits in the retinal degeneration sTg-IRBP: HEL mouse model.

Liu YH, Mölzer C, Milne GC, Kuffová L, Forrester JV.Data Brief. 2018 Dec 6;22:140-144. doi: 10.1016/j.dib.2018.12.007. eCollection 2019 Feb.PMID: 30581918IF 0.970

Retinal Genomics and Therapy

Postmitotic Cone Migration Mechanisms in the Mammalian Retina.

Carvalho LS, Mellough CB.Adv Exp Med Biol. 2019;1185:489-493. doi: 10.1007/978-3-030-27378-1_80. Review.PMID: 31884659IF 2.126

The Role of the Voltage-Gated Potassium Channel Proteins Kv8.2 and Kv2.1 in Vision and Retinal Disease: Insights from the Study of Mouse Gene Knock-Out Mutations.

Hart NS, Mountford JK, Voigt V, Fuller-Carter P, Barth M, Nerbonne JM, Hunt DM, Carvalho LS.eNeuro. 2019 Feb 25;6(1). pii: ENEURO.0032-19.2019. doi: 10.1523/ENEURO.0032-19.2019. eCollection

2019 Jan-Feb.PMID: 30820446IF 3.46

Phototactic tails: Evolution and molecular basis of a novel sensory trait in sea snakes.Crowe-Riddell JM, Simões BF, Partridge JC, Hunt DM, Delean S, Schwerdt JG, Breen J, Ludington A, Gower DJ, Sanders KL.Mol Ecol. 2019 Apr;28(8):2013-2028. doi: 10.1111/mec.15022. Epub 2019 Feb 15.PMID: 30767303IF 5.855

Systematic Comparison of Retinal Organoid Differentiation from Human Pluripotent Stem Cells Reveals Stage Specific, Cell Line, and Methodological Differences.Mellough CB, Collin J, Queen R, Hilgen G, Dorgau B, Zerti D, Felemban M, White K, Sernagor E, Lako M.Stem Cells Transl Med. 2019 Jul;8(7): 694-706. doi: 10.1002/sctm.18-0267. Epub 2019 Mar 27.PMID: 30916455IF 5.962

An integrated transcriptional analysis of the developing human retina.Mellough CB, Bauer R, Collin J, Dorgau B, Zerti D, Dolan DWP, Jones CM, Izuogu OG, Yu M, Hallam D, Steyn JS, White K, Steel DH, Santibanez-Koref M, Elliott DJ, Jackson MS, Lindsay S, Grellscheid S, Lako M.Development. 2019 Jan 29;146(2). pii: dev169474. doi: 10.1242/dev.169474.PMID: 30696714IF 5.763

Lions Outback Vision

On-call telehealth for visiting optometry in regional Western Australia improves patient access to eye care.Nguyen AA, Baker A, Turner AW.Clin Exp Optom. 2019 Oct 23. doi: 10.1111/cxo.12979. [Epub ahead of print] No abstract available.PMID: 31646665IF 1.559

Evaluating the impact of the Lions Outback Vision mobile ophthalmology service.Fu S, Jeyaraj J, Turner AW.Clin Exp Ophthalmol. 2019 Apr 25. doi: 10.1111/ceo.13522. [Epub ahead of print] No abstract available.PMID: 31021477IF 2.250

Review of cataract surgery in rural north Western Australia with the Lions Outback Vision.McGlacken-Byrne A, Turner AW, Drinkwater J.Clin Exp Ophthalmol. 2019 Feb 22. doi: 10.1111/ceo.13481. [Epub ahead of print] No abstract available. PMID: 30801933IF 2.250

Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Drinkwater JJ, Davis TME, Turner AW, Bruce DG, Davis WA.Diabetes Care. 2019 Feb;42(2):288-296. doi: 10.2337/dc18-1556. Epub 2018 Dec 6.PMID: 30523034IF 15.270

Clinicians

Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial.

Mehta H, Lim LL, Nguyen V, Qatarneh D, Wickremasinghe SS, Hodgson LAB, Quin GJ, McAllister IL, Gillies MC, Fraser-Bell S.Ophthalmol Retina. 2019 Mar;3(3):286-287. doi: 10.1016/j.oret.2018.10.010. Epub 2018 Oct 25. No abstract available.PMID: 31014709IF 6.1

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL.JAMA Ophthalmol. 2019 Jan 24. doi: 10.1001/jamaophthalmol.2018.6776. [Epub ahead of print]PMID: 30676617 IF 6.167

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators.Ophthalmology. 2019 May;126(5):723-734. doi: 10.1016/j.ophtha.2018.11.025. Epub 2018 Nov 29.PMID: 30502372IF 7.732

Using the first-eye prediction error in cataract surgery to refine the refractive outcome of the second eye.

Turnbull AMJ, Barrett GD.J Cataract Refract Surg. 2019 Jul 17. pii: S0886-3350(19)30281-0. doi: 10.1016/j.jcrs.2019.04.008. [Epub ahead of print]PMID: 31326224IF 2.238

New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.

Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS.Semin Arthritis Rheum. 2019 Jun 10. pii: S0049-0172(18)30557-2. doi: 10.1016/j.

semarthrit.2019.06.004. [Epub ahead of print] Review.PMID: 31301816IF 5.072

Current ophthalmology practice patterns for syphilitic uveitis.

Oliver GF, Stathis RM, Furtado JM, Arantes TE, McCluskey PJ, Matthews JM; International Ocular Syphilis Study Group, Smith JR.Br J Ophthalmol. 2019 Jan 30. pii: bjophthalmol-2018-313207. doi: 10.1136/bjophthalmol-2018-313207. [Epub ahead of print]PMID: 31021330IF 3.615

Reduced expression of apolipoprotein E and immunoglobulin heavy constant gamma 1 proteins in Fuchs endothelial corneal dystrophy.

Kuot A, Ronci M, Mills R, Klebe S, Snibson G, Wiffen S, Loh R, Corbett M, Zhou T, Chataway T, Burdon KP, Craig JE, Urbani A, Sharma S.Clin Exp Ophthalmol. 2019 Jun 17. doi: 10.1111/ceo.13569. [Epub ahead of print] PMID: 31206232IF 2.250

Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.

Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group.Ophthalmology. 2019 Apr;126(4):540-549. doi: 10.1016/j.ophtha.2018.09.041. Epub 2018 Oct 4.PMID: 30292541IF 3.615

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.

Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group.Acta Ophthalmol. 2019 Nov;97(7): e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9.PMID: 30968592IF 3.152

Our SUPPORTERS

The Lions Eye Institute thanks and acknowledges the committed supporters who help fund our sight-saving medical research. The generosity of many individuals, businesses, government entities and institutions is greatly appreciated.

Major Institutional Support

Australian Government - Department of Health

Carl Zeiss

Christine and Kerry Stokes, Australian Capital Equity

Hawaiian

Novartis

PJ Architecture

RANZCO

Rural Health West

Santos Limited

Specsavers Pty Ltd

Telstra

The University of Western Australia

Topcon

WA Child Research Fund

WA Country Health Service

WA Department of Health

Trusts and Foundations

Constantine Family Foundation Pty Ltd

Fred Hollows Foundation

Gold Fields Australian Foundation

H & H Cohney Foundation

Hardie Foundation Pty Ltd

Lions Save-Sight Foundation

McCusker Charitable Foundation

Raine Medical Research Foundation

Stan Perron Charitable Foundation

The Patrick Foundation

Usher 1F Collaborative Inc.

Wen Giving Foundation

Wheatley Family Foundation

Special Gifts

Anonymous

Mrs Deborah Cruickshank

Mr Vernon Fountain

Mr John Giles

GKMI PTY LTD

Mr Jeffrey Hay

Mr and Mrs Norman and Freda Hogg

Mr and Mrs Lee

Lions Club of Capalaba Inc

Lions District 201W1

Mandurah Murray Mayday Inc

Mr and Mrs Milenko and Frances Mihaljevich

Mr Walter Millsteed

Mr and Mrs Brad and Carolyn Miocevich

Mr Carlo Orlando

Oxford Compounding Pty Ltd

Mr and Mrs Tom and Jean Reimers

Mrs Gwynneth Roberts

Mr and Mrs John and Lee Saleeba

Mr Keith Spence

Ms Nora Susac

Mrs Helen Sweet

Bequests

Estate of the Late Doris Allen

Anonymous

Estate of the Late Maxwell Bailey

The Alan & Lilian Cameron Charitable Endowment

Estate of the Late George Church

Estate of the Late Daphne Mauryeen D’Alton

Joyce Henderson Trust

The Harry & Margaret Kerman Trust Fund

Estate of the Late Marianne Manntz

Estate of the Late Jacqueline McAlpine

Estate of the Late Neil McArthur

Estate of the Late Elizabeth Purnell

Estate of the Late Lance Rann

Stallard Family Trust

Estate of the Late Rolph Steilberger

Estate of the Late Betty Williams

Estate of the Late Eric Withnell

Pride of LEI Pledges of Support from WA Lions Clubs

LEI Lions Club of Perth

Lions Club of Ballajura

Lions Club of Busselton

Lions Club of Claremont/Nedlands

Lions Club of Dardanup

Lions Club of Dunsborough

Lions Club of Kojonup

Lions Club of Margaret River

Lions Club of Moora

Lions Club of Morley

In January 1970, the Lions Clubs of Western Australia formed the Lions Save-Sight Foundation of WA (LSSF).

In 2020, LSSF celebrates its Golden Anniversary and records the remarkable advancements made in the treatment and research area of sight preservation in Western Australia and beyond.

From humble beginnings, when activities were mostly confined to public screenings for glaucoma in a much-travelled caravan, and testing children for Amblyopia (lazy eye), the Foundation developed rapidly.

In 1956, The University of Western Australia (UWA) established a Faculty of Medicine with 12 Specialist Chairs; Ophthalmology was not one of them. Following considerable negotiation about the provision of funding by LSSF, the Foundation was instrumental in the establishment of the Lions-UWA Chair of Ophthalmology at UWA and in the recruitment of Professor Ian Constable as the Inaugural Chair in 1974.

The Foundation grew rapidly under Professor Constable’s direction, firstly being housed at Royal Perth Hospital and later at QEII Medical Centre. By 1979, the growth of eye programmes was outstripping Lions Club resources and it was resolved to spawn out of LSSF a new and more public orientated organisation and hence the seed was sown for the establishment of the Lions Eye Institute (LEI).

Following the establishment of LEI, the LSSF continued its commitment of funding the Chair at UWA, undertaking state-wide screenings for glaucoma and assisting with funding for fit-outs of the LEI building in the 1990s and the Harry Perkins research centre in 2013.

LSSF has also assisted in the establishment of the Lions Eye Bank and underwriting funding for numerous research projects within LEI.

In this, the 50th year, the Lions Clubs of Western

Australia can look back with pride on the 1925

challenge of Helen Keller for Lions to become

“Knights of The Blind”.

The parent organisation, LSSF, looks with great satisfaction as the child, LEI, continues to grow and develop very successfully.

2020 allows us to look back on what has become “a truly golden story”.

Lion Ambrose Depiazzi OAM Chairman – Lions Save-Sight Foundation

The original mobile glaucoma detection clinic from the mid-1960s.

THE LIONS SAVE-SIGHT FOUNDATION A truly golden story

GRANTS

GrantChief Investigators

Australian Competitive Grants

NHMRC Program GrantTranslating Genetic Determinants of Glaucoma into better diagnosis and treatment

Mackey, D et al

NHMRC Centre of Research ExcellenceFrom discovery to therapy in genetic eye diseases

Mackey, D et al

NHMRC DevelopmentDeveloping a novel Glaucoma surgery for clinical use and commercialisation

Yu, D Cringle, S Morgan, B

NHMRC Partnership Glaucoma TARRGET

Mackey, D

NHMRC Practitioner FellowshipUnderstanding, predicting, preventing and treating the highly heritable, common eye diseases Myopia and Glaucoma to reduce blindness and visual impairment

Mackey, D

NHMRC MRFF Career Development FellowshipCareer Development Fellowship – Developing personalised treatment for retinal degeneration

Chen, F

NHMRC ProjectOrbital pressure alteration and interactions with intracranial and introcular pressure

Morgan, B

NHMRC ProjectYoung adult myopia: genetic and environmental associations

Mackey, D Chen, F Milne, E

Ophthalmic Research Institute of AustraliaAntisense oligonucleotide mediated modulation of CNOT3 to treat RP11

Chen, F

Retina AustraliaDual AAV retinal gene therapy approach for Usher 1F treatment

Carvalho, L

Retina AustraliaUtilising patient-specific retinal organoids in vitro to investigate the effects of an SNRNP mutation causing early onset of Retinitis pigmentosa

Mellough, C

Macular Disease Foundation AustraliaStargardt Macular Degeneration finding new genetic mutations

Chen, F

RANZCOLions Outback Vision

Turner, A

International Grants

Artema TherapeuticsTherapy for cone-rod dystrophy

Carvalho, L

Usher 1F Collaborative IncTreatment for Usher 1F

Carvalho, L

GrantChief Investigators

Government Grants

Australian Government Department of HealthLions Outback Vision

Turner, A

Government of Western Australia Department of HealthTelethon Perth Children’s Research Fund Investigating the genetic and environmental factors involved in early onset Myopia

Carvalho, L

Government of Western Australia Department of HealthLions Outback Vision

Turner, A

Government of Western Australia Department of HealthMerit Award – Project Optimising treatment strategies for improved cone rescue in visual disorders

Carvalho, L

Government of Western Australia Department of HealthRound 22 MHRIF

Government of Western Australia Department of HealthResearch Institute Support (RIS)

WA Country Health Service Turner, A

Other Grants

Perpetual Impact ProgramTraining volunteers to teach visually impaired and blind people to use specifically designed and commercially available apps

Mackey, D

Fred Hollows Foundation Turner, A

Gold Fields Australian FoundationDiabetic Retinopathy Screening Goldfields

Turner, A

McCusker Charitable FoundationOcular Tissue Engineering

Chen, F

Lions Save-Sight FoundationResearch Support

University of Western AustraliaRaine Foundation

Balaratnasin-gam, C

University of Western AustraliaResearch Collaboration Award

Lee, S

University of Western AustraliaCentre for Ophthalmology and Visual Science Infrastructure Funding

TOTAL GRANTS 2019

$6,508,641

Concise FINANCIAL REPORT

This concise financial report is an extract from the full financial report and the financial statements and specific disclosures included herein have been derived from that report.

This report cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the company as the full financial report. Further financial information can be obtained from that report which is available, free of charge, on request.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2019

2019 2018

$ $

Revenue 31,333,959 24,612,040

Materials, supplies and consumables (3,999,361) (3,239,549)

Other direct operating expenses (12,078,063) (10,405,613)

Gross surplus 15,256,535 10,966,878

Other non-operating income 1,354,816 936,789

Net fair value (loss) / gains on financial assets at fair value through profit or loss 5,974,817 (687,046)

Marketing expenses (441,326) (474,745)

Research and development (6,472,825) (5,053,895)

Occupancy costs (1,515,983) (1,407,467)

Amortisation – Right of Use Assets (181,705) -

Finance cost of lease liability (51,379) -

Administrative employee expenses (2,886,680) (2,403,217)

Administration expenses (2,553,513) (2,133,958)

Surplus / Deficit before income tax 8,482,757 (256,661)

Income tax expense - -

Surplus / Deficit after tax 8,482,757 (256,661)

Other Comprehensive Income - -

Total Comprehensive Profit / (Loss) 8,482,757 (256,661)

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389 ‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

www.grantthornton.com.au

Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000 Correspondence to: PO Box 7757 Cloisters Square Perth WA 6850 T +61 8 9480 2000 E info.wa@au.gt.com W www.grantthornton.com.au

Independent Auditor’s Report To the Members of Lions Eye Institute Limited Report on the concise financial report

Opinion We have audited the accompanying concise financial report of Lions Eye Institute Limited comprising the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended which are derived from the audited financial report of Lions Eye Institute Limited for the year ended 31 December 2019 . The concise financial report does not contain all the disclosures required by the Australian Accounting Standards and accordingly, reading the concise financial report is not a substitute for reading the audited financial report. In our opinion, the concise financial report of Lions Eye Institute Limited for the year ended 31 December 2019 complies with Accounting Standard AASB 1039 Concise Financial Reports.

Directors responsibility for the concise financial report The Directors are responsible for the preparation of the concise financial report in accordance with Accounting Standard AASB 1039 Concise Financial Reports, and the Corporations Act 2001, and for such internal control as the directors determine are necessary to enable the preparation of the concise financial report. Auditor’s responsibility Our responsibility is to express an opinion on the concise financial report based on our audit procedures which were conducted in accordance with Auditing Standard ASA 810 Engagements to Report on Summary Financial Statements. We have conducted an independent audit, in accordance with Australian Auditing Standards, of the financial report of Lions Eye Institute Limited for the year ended 31 December 2019. Our audit report on the financial report for the year was signed on 8 September 2020 and was not subject to any modification. The Australian Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report for the year is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the concise financial report. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the concise financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation of the concise financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Our procedures in respect of the concise financial report included testing that the information in the concise financial report is derived from, and is consistent with, the financial report for the year, and examination on a test basis, of evidence supporting the amounts and other disclosures which were not directly derived from the financial report for the year. These procedures have been undertaken to form an opinion whether, in all material respects, the concise financial report complies with Accounting Standard AASB 1039 Concise Financial Reports. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion Independence In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Lions Eye Institute Limited would be in the same terms if given to the directors as at the time of this auditor’s report GRANT THORNTON AUDIT PTY LTD Chartered Accountants M D Dewhurst Partner – Audit & Assurance Perth, 8 September 2020

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2019

Revaluation of available for

sale financial assets

Retained earnings Total

$ $ $

Balance at 1 January 2018 758,254 38,226,796 38,985,050

Adjustment from adoption of AASB 9 (758,254) 758,254 -

Adjusted balance at 1 January 2018 - 38,985,050 -

Deficit after tax for the year - (256,661) (256,661)

Balance 31 December 2018 - 38,728,389 38,728,389

Adjustment to balance at 1 January 2019 following application of AASB15 and AASB1058 - 6,886,269 6,886,269

Surplus after tax for the year - 8,482,757 8,482,757

Balance at 31 December 2019 - 54,097,415 54,097,415

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2019

2019 2018

$ $Cash flows from operating activities

Receipts from customers 32,025,142 25,976,705

Payments to suppliers and employees (30,532,953) (24,459,462)

Net cash provided by operating activities 1,492,189 1,517,243

Cash flows from investing activities

Interest received 117,013 96,517

Dividends received 1,270,928 865,699

Proceeds from sale of investment securities 7,989,038 4,140,000

Payments for investment securities (3,702,366) (4,423,113)

Payments for property, plant and equipment (665,090) (485,828)

Net cash provided by investing activities 5,009,523 193,275

Cash flows from financing activities

Repayment of lease interest (51,379) -

Repayment of lease liabilities (145,721) -

Net cash used in financing activities (197,100) -

Net increase in cash held 6,304,612 1,710,518

Cash and cash equivalents at the beginning of the financial year 13,776,024 12,065,506

Cash and cash equivalents at the end of the financial year 20,080,636 13,776,024

Cash and cash equivalents comprise

- Current cash at bank, on hand and deposits 10,386,652 1,350,438

- Current restricted cash 9,693,984 11,911,553

20,080,636 13,261,990

- Non-current term deposits - 514,034

20,080,636 13,776,024

Note: The adoption in 2019 of new accounting standards AASB15 (Revenue Recognition) and AASB1058 (Income of Not For Profit Entities), has resulted in a one-off increase in Retained earnings and reduction in Trade and other payables at 1 January 2019 of $6,886,269 and an increase in the 2019 Surplus of $907,955.

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2019

2019 2018

$ $CURRENT ASSETS

Cash and cash equivalents 20,080,636 13,261,990

Financial assets at fair value through profit and loss - 980,777

Trade and other receivables 4,280,602 2,801,994

Inventories 48,750 44,452

Other current assets 195,305 490,118

TOTAL CURRENT ASSETS 24,605,293 17,579,331

NON-CURRENT ASSETS

Financial assets at fair value through profit and loss 28,855,356 25,769,018

Property, plant and equipment 9,621,876 10,514,236

Right–of–use assets 1,409,869 -

TOTAL NON-CURRENT ASSETS 39,887,101 36,283,254

TOTAL ASSETS 64,492,394 53,862,585

CURRENT LIABILITIES

Trade and other payables 6,214,078 13,034,943

Lease liabilities 198,791 -

Employee provisions 2,208,048 1,609,253

TOTAL CURRENT LIABILITIES 8,620,917 14,644,196

NON-CURRENT LIABILITIES

Lease liabilities 1,247,062 -

Employee provisions 527,000 490,000

TOTAL NON-CURRENT LIABILITIES 1,774,062 490,000

TOTAL LIABILITIES 10,394,979 15,134,196

NET ASSETS 54,097,415 38,728,389

EQUITY

Retained Earnings 54,097,415 38,728,389

TOTAL EQUITY 54,097,415 38,728,389

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2019

Revaluation of available for

sale financial assets

Retained earnings Total

$ $ $

Balance at 1 January 2018 758,254 38,226,796 38,985,050

Adjustment from adoption of AASB 9 (758,254) 758,254 -

Adjusted balance at 1 January 2018 - 38,985,050 -

Deficit after tax for the year - (256,661) (256,661)

Balance 31 December 2018 - 38,728,389 38,728,389

Adjustment to balance at 1 January 2019 following application of AASB15 and AASB1058 - 6,886,269 6,886,269

Surplus after tax for the year - 8,482,757 8,482,757

Balance at 31 December 2019 - 54,097,415 54,097,415

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2019

2019 2018

$ $Cash flows from operating activities

Receipts from customers 32,025,142 25,976,705

Payments to suppliers and employees (30,532,953) (24,459,462)

Net cash provided by operating activities 1,492,189 1,517,243

Cash flows from investing activities

Interest received 117,013 96,517

Dividends received 1,270,928 865,699

Proceeds from sale of investment securities 7,989,038 4,140,000

Payments for investment securities (3,702,366) (4,423,113)

Payments for property, plant and equipment (665,090) (485,828)

Net cash provided by investing activities 5,009,523 193,275

Cash flows from financing activities

Repayment of lease interest (51,379) -

Repayment of lease liabilities (145,721) -

Net cash used in financing activities (197,100) -

Net increase in cash held 6,304,612 1,710,518

Cash and cash equivalents at the beginning of the financial year 13,776,024 12,065,506

Cash and cash equivalents at the end of the financial year 20,080,636 13,776,024

Cash and cash equivalents comprise

- Current cash at bank, on hand and deposits 10,386,652 1,350,438

- Current restricted cash 9,693,984 11,911,553

20,080,636 13,261,990

- Non-current term deposits - 514,034

20,080,636 13,776,024

Note: The adoption in 2019 of new accounting standards AASB15 (Revenue Recognition) and AASB1058 (Income of Not For Profit Entities), has resulted in a one-off increase in Retained earnings and reduction in Trade and other payables at 1 January 2019 of $6,886,269 and an increase in the 2019 Surplus of $907,955.

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2019

2019 2018

$ $CURRENT ASSETS

Cash and cash equivalents 20,080,636 13,261,990

Financial assets at fair value through profit and loss - 980,777

Trade and other receivables 4,280,602 2,801,994

Inventories 48,750 44,452

Other current assets 195,305 490,118

TOTAL CURRENT ASSETS 24,605,293 17,579,331

NON-CURRENT ASSETS

Financial assets at fair value through profit and loss 28,855,356 25,769,018

Property, plant and equipment 9,621,876 10,514,236

Right–of–use assets 1,409,869 -

TOTAL NON-CURRENT ASSETS 39,887,101 36,283,254

TOTAL ASSETS 64,492,394 53,862,585

CURRENT LIABILITIES

Trade and other payables 6,214,078 13,034,943

Lease liabilities 198,791 -

Employee provisions 2,208,048 1,609,253

TOTAL CURRENT LIABILITIES 8,620,917 14,644,196

NON-CURRENT LIABILITIES

Lease liabilities 1,247,062 -

Employee provisions 527,000 490,000

TOTAL NON-CURRENT LIABILITIES 1,774,062 490,000

TOTAL LIABILITIES 10,394,979 15,134,196

NET ASSETS 54,097,415 38,728,389

EQUITY

Retained Earnings 54,097,415 38,728,389

TOTAL EQUITY 54,097,415 38,728,389

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2019

Revaluation of available for

sale financial assets

Retained earnings Total

$ $ $

Balance at 1 January 2018 758,254 38,226,796 38,985,050

Adjustment from adoption of AASB 9 (758,254) 758,254 -

Adjusted balance at 1 January 2018 - 38,985,050 -

Deficit after tax for the year - (256,661) (256,661)

Balance 31 December 2018 - 38,728,389 38,728,389

Adjustment to balance at 1 January 2019 following application of AASB15 and AASB1058 - 6,886,269 6,886,269

Surplus after tax for the year - 8,482,757 8,482,757

Balance at 31 December 2019 - 54,097,415 54,097,415

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2019

2019 2018

$ $Cash flows from operating activities

Receipts from customers 32,025,142 25,976,705

Payments to suppliers and employees (30,532,953) (24,459,462)

Net cash provided by operating activities 1,492,189 1,517,243

Cash flows from investing activities

Interest received 117,013 96,517

Dividends received 1,270,928 865,699

Proceeds from sale of investment securities 7,989,038 4,140,000

Payments for investment securities (3,702,366) (4,423,113)

Payments for property, plant and equipment (665,090) (485,828)

Net cash provided by investing activities 5,009,523 193,275

Cash flows from financing activities

Repayment of lease interest (51,379) -

Repayment of lease liabilities (145,721) -

Net cash used in financing activities (197,100) -

Net increase in cash held 6,304,612 1,710,518

Cash and cash equivalents at the beginning of the financial year 13,776,024 12,065,506

Cash and cash equivalents at the end of the financial year 20,080,636 13,776,024

Cash and cash equivalents comprise

- Current cash at bank, on hand and deposits 10,386,652 1,350,438

- Current restricted cash 9,693,984 11,911,553

20,080,636 13,261,990

- Non-current term deposits - 514,034

20,080,636 13,776,024

Note: The adoption in 2019 of new accounting standards AASB15 (Revenue Recognition) and AASB1058 (Income of Not For Profit Entities), has resulted in a one-off increase in Retained earnings and reduction in Trade and other payables at 1 January 2019 of $6,886,269 and an increase in the 2019 Surplus of $907,955.

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2019

2019 2018

$ $CURRENT ASSETS

Cash and cash equivalents 20,080,636 13,261,990

Financial assets at fair value through profit and loss - 980,777

Trade and other receivables 4,280,602 2,801,994

Inventories 48,750 44,452

Other current assets 195,305 490,118

TOTAL CURRENT ASSETS 24,605,293 17,579,331

NON-CURRENT ASSETS

Financial assets at fair value through profit and loss 28,855,356 25,769,018

Property, plant and equipment 9,621,876 10,514,236

Right–of–use assets 1,409,869 -

TOTAL NON-CURRENT ASSETS 39,887,101 36,283,254

TOTAL ASSETS 64,492,394 53,862,585

CURRENT LIABILITIES

Trade and other payables 6,214,078 13,034,943

Lease liabilities 198,791 -

Employee provisions 2,208,048 1,609,253

TOTAL CURRENT LIABILITIES 8,620,917 14,644,196

NON-CURRENT LIABILITIES

Lease liabilities 1,247,062 -

Employee provisions 527,000 490,000

TOTAL NON-CURRENT LIABILITIES 1,774,062 490,000

TOTAL LIABILITIES 10,394,979 15,134,196

NET ASSETS 54,097,415 38,728,389

EQUITY

Retained Earnings 54,097,415 38,728,389

TOTAL EQUITY 54,097,415 38,728,389

Concise FINANCIAL REPORT

This concise financial report is an extract from the full financial report and the financial statements and specific disclosures included herein have been derived from that report.

This report cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the company as the full financial report. Further financial information can be obtained from that report which is available, free of charge, on request.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2019

2019 2018

$ $

Revenue 31,333,959 24,612,040

Materials, supplies and consumables (3,999,361) (3,239,549)

Other direct operating expenses (12,078,063) (10,405,613)

Gross surplus 15,256,535 10,966,878

Other non-operating income 1,354,816 936,789

Net fair value (loss) / gains on financial assets at fair value through profit or loss 5,974,817 (687,046)

Marketing expenses (441,326) (474,745)

Research and development (6,472,825) (5,053,895)

Occupancy costs (1,515,983) (1,407,467)

Amortisation – Right of Use Assets (181,705) -

Finance cost of lease liability (51,379) -

Administrative employee expenses (2,886,680) (2,403,217)

Administration expenses (2,553,513) (2,133,958)

Surplus / Deficit before income tax 8,482,757 (256,661)

Income tax expense - -

Surplus / Deficit after tax 8,482,757 (256,661)

Other Comprehensive Income - -

Total Comprehensive Profit / (Loss) 8,482,757 (256,661)

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389 ‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

www.grantthornton.com.au

Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000 Correspondence to: PO Box 7757 Cloisters Square Perth WA 6850 T +61 8 9480 2000 E info.wa@au.gt.com W www.grantthornton.com.au

Independent Auditor’s Report To the Members of Lions Eye Institute Limited Report on the concise financial report

Opinion We have audited the accompanying concise financial report of Lions Eye Institute Limited comprising the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended which are derived from the audited financial report of Lions Eye Institute Limited for the year ended 31 December 2019 . The concise financial report does not contain all the disclosures required by the Australian Accounting Standards and accordingly, reading the concise financial report is not a substitute for reading the audited financial report. In our opinion, the concise financial report of Lions Eye Institute Limited for the year ended 31 December 2019 complies with Accounting Standard AASB 1039 Concise Financial Reports.

Directors responsibility for the concise financial report The Directors are responsible for the preparation of the concise financial report in accordance with Accounting Standard AASB 1039 Concise Financial Reports, and the Corporations Act 2001, and for such internal control as the directors determine are necessary to enable the preparation of the concise financial report. Auditor’s responsibility Our responsibility is to express an opinion on the concise financial report based on our audit procedures which were conducted in accordance with Auditing Standard ASA 810 Engagements to Report on Summary Financial Statements. We have conducted an independent audit, in accordance with Australian Auditing Standards, of the financial report of Lions Eye Institute Limited for the year ended 31 December 2019. Our audit report on the financial report for the year was signed on 8 September 2020 and was not subject to any modification. The Australian Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report for the year is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the concise financial report. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the concise financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation of the concise financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Our procedures in respect of the concise financial report included testing that the information in the concise financial report is derived from, and is consistent with, the financial report for the year, and examination on a test basis, of evidence supporting the amounts and other disclosures which were not directly derived from the financial report for the year. These procedures have been undertaken to form an opinion whether, in all material respects, the concise financial report complies with Accounting Standard AASB 1039 Concise Financial Reports. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion Independence In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Lions Eye Institute Limited would be in the same terms if given to the directors as at the time of this auditor’s report GRANT THORNTON AUDIT PTY LTD Chartered Accountants M D Dewhurst Partner – Audit & Assurance Perth, 8 September 2020

Concise FINANCIAL REPORT

This concise financial report is an extract from the full financial report and the financial statements and specific disclosures included herein have been derived from that report.

This report cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the company as the full financial report. Further financial information can be obtained from that report which is available, free of charge, on request.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2019

2019 2018

$ $

Revenue 31,333,959 24,612,040

Materials, supplies and consumables (3,999,361) (3,239,549)

Other direct operating expenses (12,078,063) (10,405,613)

Gross surplus 15,256,535 10,966,878

Other non-operating income 1,354,816 936,789

Net fair value (loss) / gains on financial assets at fair value through profit or loss 5,974,817 (687,046)

Marketing expenses (441,326) (474,745)

Research and development (6,472,825) (5,053,895)

Occupancy costs (1,515,983) (1,407,467)

Amortisation – Right of Use Assets (181,705) -

Finance cost of lease liability (51,379) -

Administrative employee expenses (2,886,680) (2,403,217)

Administration expenses (2,553,513) (2,133,958)

Surplus / Deficit before income tax 8,482,757 (256,661)

Income tax expense - -

Surplus / Deficit after tax 8,482,757 (256,661)

Other Comprehensive Income - -

Total Comprehensive Profit / (Loss) 8,482,757 (256,661)

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389 ‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

www.grantthornton.com.au

Level 43, Central Park 152-158 St Georges Terrace Perth WA 6000 Correspondence to: PO Box 7757 Cloisters Square Perth WA 6850 T +61 8 9480 2000 E info.wa@au.gt.com W www.grantthornton.com.au

Independent Auditor’s Report To the Members of Lions Eye Institute Limited Report on the concise financial report

Opinion We have audited the accompanying concise financial report of Lions Eye Institute Limited comprising the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended which are derived from the audited financial report of Lions Eye Institute Limited for the year ended 31 December 2019 . The concise financial report does not contain all the disclosures required by the Australian Accounting Standards and accordingly, reading the concise financial report is not a substitute for reading the audited financial report. In our opinion, the concise financial report of Lions Eye Institute Limited for the year ended 31 December 2019 complies with Accounting Standard AASB 1039 Concise Financial Reports.

Directors responsibility for the concise financial report The Directors are responsible for the preparation of the concise financial report in accordance with Accounting Standard AASB 1039 Concise Financial Reports, and the Corporations Act 2001, and for such internal control as the directors determine are necessary to enable the preparation of the concise financial report. Auditor’s responsibility Our responsibility is to express an opinion on the concise financial report based on our audit procedures which were conducted in accordance with Auditing Standard ASA 810 Engagements to Report on Summary Financial Statements. We have conducted an independent audit, in accordance with Australian Auditing Standards, of the financial report of Lions Eye Institute Limited for the year ended 31 December 2019. Our audit report on the financial report for the year was signed on 8 September 2020 and was not subject to any modification. The Australian Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report for the year is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the concise financial report. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the concise financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation of the concise financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Our procedures in respect of the concise financial report included testing that the information in the concise financial report is derived from, and is consistent with, the financial report for the year, and examination on a test basis, of evidence supporting the amounts and other disclosures which were not directly derived from the financial report for the year. These procedures have been undertaken to form an opinion whether, in all material respects, the concise financial report complies with Accounting Standard AASB 1039 Concise Financial Reports. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion Independence In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Lions Eye Institute Limited would be in the same terms if given to the directors as at the time of this auditor’s report GRANT THORNTON AUDIT PTY LTD Chartered Accountants M D Dewhurst Partner – Audit & Assurance Perth, 8 September 2020